WO2007076699A1 - Composition pharmaceutique contenant un extrait de chenopodium ambrosioides et son procédé de préparation et son application - Google Patents

Composition pharmaceutique contenant un extrait de chenopodium ambrosioides et son procédé de préparation et son application Download PDF

Info

Publication number
WO2007076699A1
WO2007076699A1 PCT/CN2006/003691 CN2006003691W WO2007076699A1 WO 2007076699 A1 WO2007076699 A1 WO 2007076699A1 CN 2006003691 W CN2006003691 W CN 2006003691W WO 2007076699 A1 WO2007076699 A1 WO 2007076699A1
Authority
WO
WIPO (PCT)
Prior art keywords
oil
extract
schizonepeta
preparation
pharmaceutical composition
Prior art date
Application number
PCT/CN2006/003691
Other languages
English (en)
French (fr)
Inventor
Feng Wei
Zhengliang Ye
Jun Gao
Chongnian Luo
Dekun Li
Jianming Chen
Yonghong Zhu
Junfeng Xiong
Xiaoli Zheng
Guangming Zhang
Ying Zhao
Original Assignee
Tianjin Tasly Pharmaceutical Co. Ltd., China
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN2005101353590A external-priority patent/CN1990007B/zh
Priority claimed from CN2005101353586A external-priority patent/CN1990006B/zh
Priority claimed from CN2006101365003A external-priority patent/CN101172132B/zh
Application filed by Tianjin Tasly Pharmaceutical Co. Ltd., China filed Critical Tianjin Tasly Pharmaceutical Co. Ltd., China
Priority to KR1020087018649A priority Critical patent/KR101164516B1/ko
Priority to JP2008547835A priority patent/JP5844954B2/ja
Priority to US12/159,609 priority patent/US8361515B2/en
Priority to EP06840721A priority patent/EP1982705B8/en
Priority to CA2635610A priority patent/CA2635610C/en
Publication of WO2007076699A1 publication Critical patent/WO2007076699A1/zh
Priority to HK08111964.1A priority patent/HK1119938A1/xx
Priority to US13/725,265 priority patent/US8586108B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Definitions

  • the present invention relates to a plant extract, in particular, a traditional Chinese medicine extract of Nepeta, a preparation containing the extract and a preparation method thereof; and the present invention also relates to the preparation of the stomach for treating gastritis caused by Helicobacter pylori, stomach Application in ulcer drugs. Background technique
  • Stomach disease is a common clinical disease, frequently-occurring disease, and high incidence. Since 1983 Marshall and Warren reported on the "Lancet” [Warren JR, Marshall BJ. Lancet, 1983, 1: 1273-1275], they cultivated a spiral aerobic bacterium in the human gastric mucosa, named After Helicobacter Pylori (HP) and proved that this bacterium is related to gastritis, people's understanding of human upper gastrointestinal diseases has revolutionized (Xu Ling, Journal of First Military Medical University, 1995, 15 (4) : 360 -361). With the deepening of research, people have gradually recognized that Helicobacter pylori is the cause of various stomach diseases.
  • Mo Jianzhong introduced the profile of 55 groups of drugs abroad (Mo Jianzhong, Chinese Journal of Digestion, 1995, 15 (3 ): 164); Huang Xuerui and other reports on the combination of omeprazole and antibiotics (Huang Xuerui, Chang Heling) Northwest Pharmaceutical Journal, 1998, 13(1): 33-34).
  • the above-mentioned western medicines are mainly prodrug inhibitors combined with antibacterial drugs, which have large side effects and antibiotics are prone to drug resistance and dysbacteriosis.
  • One of the main objects of the present invention is to provide an extract of Schizonepeta chinensis which is easy to obtain raw materials, has a remarkable curative effect, and has a small side effect, in view of the deficiencies of the prior art.
  • Another object of the invention is to provide a composition comprising the extract.
  • the invention also provides the use of the extract and the composition containing the extract for preparing a medicament for treating gastritis and gastric ulcer caused by Helicobacter pylori infection.
  • the term "E. sinensis extract” as used in the present invention is also referred to as "C. chinensis volatile oil”.
  • the invention is implemented by the following technical solutions.
  • the extract of the schizonepeta of the present invention by GC-MS analysis, has the following two peaks in the obtained mass spectrum:
  • Peak 1 retention time 8.0 ⁇ 9.5 minutes, fragment ion mass-to-charge ratio is 121, 93;
  • Peak 2 Retention time 9 to 10.0 minutes, fragment ion mass-to-charge ratio is 120, 119, 134; Further, by GC-MS analysis, the obtained spectrum also contains the following two peaks: Peak 3: Retention time 10.0 ⁇ 20.5 Minutes, fragment ion mass-to-charge ratio is 119, 121, 136; peak 4: retention time 15.0 ⁇ 20.5 minutes, fragment ion mass-to-charge ratio is 135, 43, 97.
  • the obtained spectrum also contains the following two peaks: Peak 5: retention time 5.5 ⁇ 15.5 minutes, fragment ion mass-to-charge ratio is 93, 91;
  • Peak 6 Retention time 12.5 ⁇ 20.0 minutes, fragment ion mass-to-charge ratio is 71, 126, 69, 41.
  • Sample preparation dissolving the extract of Schizonepeta in ethyl acetate solution
  • Heating program starting from 80 ,, going through 100 ° C, 150 ° C, heating up to 300 ° C temperature program end; vaporization chamber temperature: 250 ° C ; carrier gas: high purity ⁇ (99.999%); carrier gas flow rate: l. OmL / min; injection volume: (ethyl acetate solution); split ratio: 30:1;
  • Ion source ⁇ source; ion source temperature: 230 ° C ; quadrupole temperature: 150 ° C; multiplier voltage: 1781 V; interface temperature: 280 ° C; mass scanning range: 10-550 amu.
  • the Schizonepeta extract of the present invention contains the following components:
  • the extract of the schisandra chinensis of the present invention contains, in weight percentage, 15 to 35% of ⁇ -terpinene, 15 to 25% of cymene, and 10 to 20% of scorpion, ⁇ . - Iso-terpinene ( ⁇ -Terpinolene) 32 ⁇ 40%.
  • the extract of Schizonepeta chinensis according to the present invention contains, in weight percentage, the following components: a-terpinene 20-30%, cymene 18-22%, and sputum 12-18%, A-isoterenene 32 ⁇ 35°/ 0 . Further preferably, the extract of Schizonepeta chinensis according to the present invention contains, by weight percentage, the following components: ⁇ -terpinene 22-25%, cymene 19-21%, and scorpion 13-15%, --isoterpinene 32 ⁇ 33%.
  • the extract of the schisandra chinensis of the present invention contains, in weight percentage, the following components: ⁇ -terpinene 15 to 35%, cymene 15 to 25%, and scorpion 10 to 20%, --isoterenene 32 ⁇ 40%, ⁇ -terpinene ( ⁇ -Terpinene) 0.5-0.7%, limonene 0.6-0.8%;
  • the extract of Schizonepeta chinensis according to the present invention contains, in weight percentage, the following components: ⁇ -terpinene 22-25%, cymene 19-21%, and scorpion 13-15%, ⁇ -isoterpinene 32 ⁇ 33%, ⁇ -terpinene 0.5 ⁇ 0.6%, and limonene 0.6 ⁇ 0.7%.
  • the present invention also provides a pharmaceutical composition
  • a pharmaceutical composition comprising the extract, which comprises the extract of E. chinensis as described above and a pharmaceutically acceptable excipient.
  • compositions provided herein may also contain other active ingredients.
  • the active ingredient described in the pharmaceutical composition provided by the present invention is hydrophyllin oil.
  • compositions provided by the present invention can be formulated into various pharmaceutical preparations.
  • the preparations include, but are not limited to, capsules, hard capsules, soft capsules (also known as capsules), injections, instillation solutions, powder injections, granules, tablets, granules, powders, oral liquids, sugar coatings. Tablets, film-coated tablets, enteric coated tablets, buccal preparations, pills, ointments, dans, sprays, pills, orally disintegrating tablets, pellets, aerosols, and the like.
  • the capsule may be a common capsule or a self-emulsifying preparation expressed in the form of a capsule.
  • the preparation of the pharmaceutical composition of the present invention having the extract of Nepeta chinensis as an active ingredient is a capsule, consisting of a capsule content and a capsule, and the contents of the capsule are the extract of Schizonepeta and vegetable oil. .
  • the vegetable oil described therein is an acceptable vegetable oil such as peanut oil, rapeseed oil, tea seed oil or the like from which solid fatty acids are removed.
  • the weight ratio of the extract of the schizonepeta and the vegetable oil is 1: (1 to 3); the preferred weight ratio is 1: (1 to 2); and the optimum weight ratio is 1:1.
  • the capsule material comprises gelatin and a plasticizer, wherein the plasticizer is selected from the group consisting of glycerin, xylitol, sorbitol, hydrogenated corn syrup; preferably from glycerol, xylitol; and most preferably glycerin.
  • the plasticizer is selected from the group consisting of glycerin, xylitol, sorbitol, hydrogenated corn syrup; preferably from glycerol, xylitol; and most preferably glycerin.
  • the preparation of the present invention having the extract of E. striata as an active ingredient is prepared as a self-emulsifying preparation, and the so-called self-emulsifying preparation is a precursor of emulsion formation, and comprises a drug, an oil phase, a surfactant, and a co-surfactant. Solid or uniform, transparent liquid dosage form.
  • the basic feature of this system is the spontaneous formation of oil-in-water emulsions in the gastrointestinal tract or at ambient temperature (usually 37 ⁇ body temperature) and gentle agitation, thus relying on fine
  • the increase in the specific surface area of the small oil droplets significantly improves the dissolution of the water-insoluble drug in the gastrointestinal tract, greatly increases the bioavailability of the drug, and the formed emulsion also reduces the stimulation of the gastrointestinal tract by the drug. It can overcome the problems of instability of traditional preparations, low bioavailability, cumbersome preparation process, and large dosage.
  • the weight ratio of each component of the self-emulsifying preparation of the invention is: 1-95% of the extract of Nepeta, 4 ⁇ 39% of the rapeseed salad oil, 1 ⁇ 45% of the surfactant, 0 ⁇ 15% of the auxiliary surfactant; Preferably, the weight ratio is: 20 ⁇ 70% of the extract of Nepeta, 10 ⁇ 30% of the rapeseed salad oil, 15 ⁇ 40% of the surfactant, and 5 ⁇ 10% of the auxiliary surfactant.
  • the self-emulsifying preparation of the present invention may further comprise a water scented flower oil, and the weight ratio of each component is: 1 to 95% of the schizonepeta extract and the water scented flower oil, and 4 to 39% of the rapeseed salad oil. , surfactant 1 ⁇ 45%, co-surfactant 0 ⁇ 15%; preferred weight ratio: earthworm mustard extract and water flower oil 20 ⁇ 70%, rapeseed salad oil 10 ⁇ 30%, surface active 15 ⁇ 40% of the agent, 5 ⁇ 10% of the auxiliary surfactant.
  • the weight ratio of the volatile oil of the schizonepeta and the water scented flower oil is (1 ⁇ 5):1, and the weight ratio is preferably 3:1.
  • the surfactant is selected from the group consisting of polyoxyethylene castor oil condensate, polyoxyethylene hydrogenated castor oil condensate, polysorbate, phospholipid, etc., alone or in combination.
  • the polyoxyethylene castor oil condensate is a condensate containing a different amount of polyoxyethylene bonds per molecule, such as polyoxyethylene (35) castor oil, polyoxyethylene (60) castor oil, and the like.
  • the polyoxyethylene hydrogenated castor oil condensate is a condensate containing a different amount of polyoxyethylene bonds per molecule, such as polyoxyethylene (35) hydrogenated castor oil, polyoxyethylene (60) hydrogenated castor oil, and the like.
  • the polysorbate is preferably, but not limited to, polysorbate 60, polysorbate 80.
  • the phospholipids are derived from natural phospholipids and synthetic phospholipids, natural phospholipids including egg yolk lecithin, soy lecithin; synthetic phospholipids including but not limited to dipalmitoylphosphatidylcholine, distearoylphosphatidylcholine, dimyristoyl Phosphatidylcholine and the like.
  • the co-surfactant is selected from the group consisting of ethanol, ethylene glycol, propylene glycol, n-butanol, isopropanol, polyethylene glycol 4000, and polyethylene glycol 6000.
  • the present invention also provides a process for the preparation of a pharmaceutical composition comprising an extract of Schizonepeta, the method comprising the steps of:
  • Nepeta chinensis extract obtained by conventional extraction method
  • the extract of Schizonepeta can be prepared by a conventional method for extracting volatile oil, such as steam distillation, organic solvent soaking (solvent reflux), simultaneous distillation-extraction (SDE), supercritical carbon dioxide extraction, cold pressing, etc.
  • steam distillation supercritical carbon dioxide extraction
  • optimal steam distillation is preferred.
  • the optimal extraction step is as follows: Put the seeds of Nepeta chinensis or whole grass into a distillation pot, pass steam in the collector, keep the extraction temperature at 85 ⁇ 100 °C, and distill for a certain time, for example 40 Minutes, collect volatile oil from the schizonepeta.
  • the water mass flower oil can be prepared by a conventional volatile oil extraction method, such as steam distillation, organic solvent soaking method (solvent reflux method), simultaneous distillation-extraction method (SDE), supercritical carbon dioxide extraction method, cold pressing method, etc.; Steam distillation, supercritical carbon dioxide extraction; more preferably steam distillation; best
  • a conventional volatile oil extraction method such as steam distillation, organic solvent soaking method (solvent reflux method), simultaneous distillation-extraction method (SDE), supercritical carbon dioxide extraction method, cold pressing method, etc.
  • SDE simultaneous distillation-extraction method
  • supercritical carbon dioxide extraction more preferably steam distillation
  • the steps of extracting the water scented flower oil are as follows: The water stalks and leaves are placed in a distillation pot, steam is passed through the collector, the extraction temperature is maintained at 85 to 100 ° C, and the volatile oil is collected by distillation for a certain period of time, for example, 40 minutes.
  • the extraction step is: placing the seed of the mustard seed or the whole grass and the water flower stems and leaves In the distillation pot, steam is passed through the collector, and the extraction temperature is maintained at 85 to 100 ° C, and the volatile oil is collected by distillation for a certain period of time, for example, 40 minutes.
  • the preparation method of the pharmaceutical composition of the present invention wherein the prepared composition is a capsule, the preparation method comprises taking medicinal gelatin and a plasticizer, dissolving and filtering in distilled water to prepare a gelatin solution; and dissolving the diluted soil with vegetable oil
  • the mustard volatile oil is obtained as a raw material oil; the raw material oil and the gelatin solution are added to the capsule production equipment to prepare a rubber pellet containing the oily liquid.
  • the plasticizer described therein is selected from the group consisting of glycerin, xylitol, sorbitol and hydrogenated corn syrup.
  • the preparation method of the pharmaceutical composition of the present invention wherein the prepared composition is a self-emulsifying preparation, and the preparation method comprises weighing the Schizonepeta extract, Schizonepeta extract, and water flower oil, rapeseed salad oil according to a prescribed amount.
  • the surfactant or the co-surfactant is heated in a water bath at 30 to 80 ° C or ultrasonically to a uniform, transparent solution, and then prepared into a soft capsule or a hard capsule preparation.
  • the surfactant is selected from the group consisting of polyoxyethylene castor oil condensate, polyoxyethylene hydrogenated castor oil condensate, polysorbate, and phospholipid.
  • the polyoxyethylene castor oil condensate is selected from the group consisting of polyoxyethylene (35) castor oil, polyoxyethylene (60) castor oil; and the polyoxyethylene hydrogenation
  • the castor oil condensate is selected from the group consisting of polyoxyethylene (35) hydrogenated castor oil, polyoxyethylene (60) hydrogenated castor oil
  • the polysorbate is selected from the group consisting of polysorbate 60, polysorbate 80; From egg yolk lecithin, soy lecithin, dipalmitoylphosphatidylcholine, distearoylphosphatidylcholine, dimyristoylphosphatidylcholine.
  • the co-surfactant is selected from the group consisting of ethanol, ethylene glycol, propylene glycol, n-butanol, isopropanol, polyethylene glycol 4000, and polyethylene glycol 6000.
  • the extract of the schizonepeta of the present invention and the composition containing the extract can be used for treating gastric diseases such as gastritis and peptic ulcer caused by Helicobacter pylori infection.
  • the invention extracts the active ingredient of the traditional Chinese medicine schisandra chinensis as a raw material for gastric diseases such as gastritis and peptic ulcer caused by Helicobacter pylori infection, the material is easy to obtain, the production process is simple, easy and easy to control quality; the curative effect is remarkable, the side effect is small and Easy to use.
  • the self-emulsifying preparation further adopts the targeting property, is more easily absorbed, thereby increasing the bioavailability; at the same time, the adverse reaction of the patient can be alleviated, and the influence of unstable factors such as moisture and oxygen is avoided, thereby enhancing the stability of the drug.
  • Fig. 2 Total ion flow diagram of volatile oil from Nepeta chinensis in Hunan province, China
  • Figure 3 Total ion flow diagram of volatile oil from Nepeta chinensis in Shaanxi Republic, China
  • Figure 5 shows the parasitic hydrocarbon mass spectrum
  • Test Example 1 GC/MS analysis of volatile oil from Nepeta
  • the medicinal material was newly collected from Fujian, and was identified by the Quality Inspection Department of Tianjin Tianshili Pharmaceutical Co., Ltd. as the genus Nelumbosperm.
  • the schizonepeta produced in Hunan and Shaanxi is provided by Tianjin Tianshili Pharmaceutical Co., Ltd. Hunan and Shaanxi medicinal planting bases.
  • the GC/MS is HP6890/HP5973 GC/MS (Agilent, USA).
  • Ethyl acetate (analytical grade, Tianjin Chemical Reagent 2); anhydrous sodium sulfate (analytical grade, Tianjin Chemical Reagent 2); deionized water (manufactured by Tasly Pharmaceutical Co., Ltd.).
  • Heating program starting from 80 ° C, holding at 80 ° C for 10 minutes, 4 ⁇ / min to 100 ° C for 5 minutes, 5 ° C / min to 150 ° C for 5 minutes, then 20 ° C/min is heated to 300 ° C for 2.5 minutes, and the temperature rising program ends;
  • Vaporization chamber temperature 250 ⁇ ; carrier gas: high purity hydrazine (99.999%); carrier gas flow rate: l.OmL / min; injection amount: (ethyl acetate solution); split ratio: 30:1. 3.2. Mass spectrometry conditions
  • Ion source EI source; ion source temperature: 230 °C; quadrupole temperature: 15CTC; electron energy: 70ev ; emission current: 34.6UA; multiplier voltage: 1781V; interface temperature: 280°C ; mass scan range: 10 -550amu.
  • the peak area normalization method was used to calculate the relative percentage of each chemical component in the volatile oil.
  • Gyiateul tlhtoi Is 3 ⁇ 4%py53 ⁇ 45y 0.17445 8 Cnehlleor Ca-- %. 72 ⁇ .0 00 15186 C10alenar 3C--- %y3 ⁇ 46l7 0.073115 21dealdehiller p-- - 3 ⁇ 4w. I7%l78 14. 585612H Cdoleari Asc-- 14yS7%8 0.28 89830 CHolhmT m--- i63 ⁇ 4. 0%8 0.56384 528H ⁇ -- 70% 0.49997 572-- Sie.83% 32498662 5H---
  • Volatile oil of E. sinensis Prepared according to the method of Example 5, yellow oil, production batch number: 20040129, provided by Tianjin Tianshili Pharmaceutical Co., Ltd., the volumetric flask is kept in a sealed state, diluted with vegetable oil before use, and the required concentration is given to the animal. Administered by gavage (ig).
  • Ranitidine produced by Shijiazhuang Siji Co., Ltd., batch number: 030836.
  • Vegetable oil Fulinmen natural grain blending oil, commercially available, production batch number: 03110405.
  • mice weighing 18-22 (g), male and female.
  • Wistar rats weighing 160-220 (g), half male and half female.
  • the dose was ig administered as shown in Table 2, once a day for 13 consecutive days, and the model control group i g was given the same volume of vegetable oil. Molding was performed 2 hours after the third administration. Fasting for 24 hours before modeling, animal ether anesthesia, abdominal shaving disinfection, cut a small mouth along the midline under the xiphoid process, gently pull the stomach out, and inject 40% acetic acid 10 ⁇ 1 into the appetite near the pyloric gland. The stomach is returned to the abdominal cavity and the wound is sutured. Continued administration after surgery. After fasting for 24 hours after the last administration, the animals were sacrificed by urethane anesthesia, the abdominal cavity was dissected, the whole stomach was taken out, and the stomach was cut along the big curve.
  • the animals were anesthetized, the abdomen was dissected, the cardia was ligated, the whole stomach was removed, and the stomach was dissected along the stomach. After the saline was rinsed, the 1% formaldehyde was fixed for 10 minutes and measured with a precision caliper. The diameter of the ulcer point, the sum of the areas of the ulcer points of each rat, indicates the size of the ulcer, and the total area of the ulcer is divided into five grades according to the Okabe method as the ulcer index.
  • mice with Km seed agent, weighing 18-22 (g), male and female, randomly divided into groups of 10 each.
  • the doses shown in Table 4 were administered ig, once a day for 3 consecutive days, and the control group ig was given the same volume of vegetable oil. 40 minutes after the last administration (24 hours after the animals were fasted before the administration), each group of animals was intragastrically administered with 2% Indian ink (prepared with 5% gum arabic solution), and the control group ig was given the same volume of 5% Arab. Glue solution. After 20 minutes, the mice were sacrificed by cervical dislocation, the abdomen was dissected, the entire stomach and small intestine were gently taken out and separated, and the plate was placed on a wax plate.
  • the length of the pylorus to the ileocecal area was measured, and the length of the small intestine was measured. Then the pylorus was pushed to the ink propulsion. The length of the leading edge is the length of the small intestine.
  • the percentage of advancement of the small intestine was calculated as compared with the length of the upper small intestine. The average percentage of advancement of the animals in each group was compared with the average percentage of the control group. The results (see Table 4) showed that the percentage of intestinal high- and medium-dose intestinal propellant was significantly lower than that of the control group, indicating that the drug significantly inhibited intestinal motility.
  • the drug is ground into an emulsion with egg yolk. After autoclaving, it is mixed into the medium by dilution. 100 ⁇ of the prepared bacterial solution is added to each dish, and evenly spread. After 72 hours of incubation in a micro-anaerobic environment at 37 ° C, the results are observed.
  • the concentration of the drug in the Petri dish without HP growth was the minimum inhibitory concentration of the volatile oil of S. chinensis to HP.
  • the results showed that the minimum inhibitory concentration of the volatile oil samples of S. chinensis was 0.097 mg/ml, indicating significant inhibition of H. pylori. Table 5. Inhibition of Helicobacter pylori in vitro by Volatile Oil of Nepeta
  • gelatin 100 parts of gelatin is added to 120 parts of water to cause water swelling, and 30 parts of glycerin is heated to 60 ° C, and the expanded gelatin is added, stirred, and melted to obtain a gelatin solution, which is kept for use;
  • the volatile oil of the schisandra chinensis prepared in Example 1 was added to the vegetable oil, and the weight ratio of the vegetable oil to the volatile oil of the schizonepeta was 3:1; and the mixture was stirred to obtain a raw material oil;
  • the gelatin solution and the raw material oil are put into an automatic rotary rolling bag machine, and pressed into a rubber pellet containing an oily liquid of 100 mg/grain, and the pellets are shaped, dried, washed, and sterilized, and packaged.
  • gelatin 100 parts of gelatin is added to 140 parts of water to cause water swelling, and 30 parts of glycerin is heated to 70 ° C, and the expanded gelatin is added, stirred, and melted to obtain a gelatin solution, which is kept for use;
  • the volatile oil of the schisandra chinensis prepared in Example 2 was added to the vegetable oil, and the weight ratio of the vegetable oil to the volatile oil of the schisandra chinensis was 2:1; and the mixture was stirred to obtain a raw material oil;
  • the gelatin solution and the raw material oil are placed in an automatic rotary rolling bag machine, and pressed into a rubber pellet containing 90 mg/granule of oily liquid.
  • the pellets are shaped, dried, washed, and sterilized, and packaged.
  • gelatin 100 parts of gelatin is added to 130 parts of water to cause water swelling, and 30 parts of glycerin is heated to 80 ° C, and the expanded gelatin is added, stirred, and melted to obtain a gelatin solution, which is kept for use;
  • the volatile oil of the schisandra chinensis prepared in Example 3 was added to the vegetable oil, and the weight ratio of the vegetable oil to the volatile oil of the schisandra chinensis was 1.5:1; and the mixture was stirred to obtain a raw material oil;
  • the gelatin solution and the raw material oil are put into a dropping machine to prepare a rubber pellet containing 90 mg/granule of oily liquid, and the pellet is shaped, dried, washed, and sterilized, and packaged.
  • Example 13 Preparation of Capsules 100 parts of gelatin is added to 140 parts of water to cause water swelling, and 35 parts of glycerin is heated to 70 ⁇ , the expanded gelatin is added, stirred, and melted to obtain a gelatin solution, which is kept for use;
  • the volatile oil of the schisandra chinensis prepared in Example 5 is added to the vegetable oil, and the weight ratio of the vegetable oil to the volatile oil of the schisandra chinensis is 1 : 1;
  • the gelatin solution and the raw material oil are put into a dropping machine to prepare a rubber pellet containing 80 mg/granule of oily liquid, and the pellets are shaped, dried, washed, and sterilized, and packaged.
  • gelatin 100 parts of gelatin is added to 120 parts of water to make it absorb water, and 40 parts of xylitol is heated to 80 Torr. The expanded gelatin is added, stirred and melted to obtain a gelatin solution, which is kept for use;
  • the volatile oil of the schisandra chinensis prepared in Example 4 is added to the vegetable oil, and the weight ratio of the vegetable oil to the volatile oil of the schisandra chinensis is 1 : 1;
  • the gelatin solution and the raw material oil are put into a dropping machine to prepare a rubber pellet containing 80 mg/granule of oily liquid, and the pellets are shaped, dried, washed, and sterilized, and packaged.
  • gelatin 100 parts of gelatin is added to 120 parts of water to make it absorb water, and 30 parts of glycerin is heated to 60 Torr. The expanded gelatin is added, stirred, and melted to obtain a gelatin solution, which is kept for use;
  • the volatile oil of the schisandra chinensis prepared in Example 5 was added to the vegetable oil, and the weight ratio of the vegetable oil to the volatile oil of the schizonepeta was 1.1:1; and the mixture was stirred to obtain a raw material oil;
  • the gelatin solution and the raw material oil are put into a dropping machine to prepare a rubber pellet containing 80 mg/granule of oily liquid, and the pellets are shaped, dried, washed, and sterilized, and packaged.
  • gelatin 100 parts of gelatin is added to 120 parts of water to cause water swelling, and 30 parts of sorbitol is heated to 80 ° C, and the expanded gelatin is added, stirred, and melted to obtain a gelatin solution, which is kept for use;
  • the volatile oil of the schisandra chinensis prepared in Example 5 was added to the vegetable oil, and the weight ratio of the vegetable oil to the volatile oil of the schizonepeta was 1.3:1; and the mixture was stirred to obtain a raw material oil;
  • gelatin 100 parts of gelatin is added to 110 parts of water to cause water swelling, and 40 parts of hydrogenated corn syrup is heated to 80 ° C, and the expanded gelatin is added, stirred, and melted to obtain a gelatin solution, which is kept for use;
  • the volatile oil of the schisandra chinensis prepared in Example 5 was added to the vegetable oil, and the weight ratio of the vegetable oil to the volatile oil of the schisandra chinensis was 2.5:1; and the mixture was stirred to obtain a raw material oil;
  • the gelatin solution and the raw material oil are charged into a transfer mode pellet manufacturing machine to prepare an oily liquid containing 90 mg/granule.
  • Capsules, capsules are shaped, dried, washed, disinfected, and packaged.
  • gelatin 100 parts of gelatin is added to 140 parts of water to cause water swelling, and 30 parts of glycerin is heated to 70 ° C, and the expanded gelatin is added, stirred, and melted to obtain a gelatin solution, which is kept for use;
  • the volatile oil of the schisandra chinensis prepared in Example 2 was added to the vegetable oil, and the weight ratio of the vegetable oil to the volatile oil of the schisandra chinensis was 1:1, and sheared to a suitable dispersion by a shearing type milk homogenizer to obtain a raw material oil;
  • the gelatin solution and the raw material oil are charged into a transfer mode pellet manufacturing machine to prepare a rubber pellet containing 120 mg/granule of oily liquid, and the pellets are shaped, dried, washed, and sterilized, and packaged.
  • gelatin 100 parts of gelatin is added to 120 parts of water to cause water swelling, and 30 parts of sorbitol is heated to 60 ° C, and the expanded gelatin is added, stirred, and melted to obtain a gelatin solution, which is kept for use;
  • the volatile oil of the schisandra chinensis prepared in Example 5 was added to the vegetable oil, and the weight ratio of the vegetable oil to the volatile oil of the schisandra chinensis was 2:1, and sheared to a suitable dispersion by a shear type milk homogenizer to obtain a raw material oil;
  • the gelatin solution and the raw material oil are put into a dropping machine to prepare a rubber pellet containing 150 mg/granule of oily liquid, and the pellets are shaped, dried, washed, and sterilized, and packaged.
  • gelatin 100 parts of gelatin is added to 130 parts of water to make it absorb water, and 30 parts of glycerin is heated to 70V. The expanded gelatin is added, stirred and melted to obtain a gelatin solution, which is kept for use;
  • the volatile oil of the schisandra chinensis prepared in Example 4 was added to the vegetable oil, and the weight ratio of the vegetable oil to the volatile oil of the schisandra chinensis was 2.5:1, and sheared to a suitable dispersion by a shearing type milk homogenizer to obtain a raw material oil;
  • the gelatin solution and the raw material oil are put into a dropping machine to prepare a rubber pellet containing 140 mg/granule of oily liquid, and the pellets are shaped, dried, washed, sterilized, and packaged.
  • the volatiles of the schizonepeta vulgaris in Example 4 were mixed with 17 g of light magnesium oxide, and 17 g of starch, 17 g of lactose, and 0.5% of HPMC aqueous solution were added as a binder to prepare a 300 mg/tablet tablet, 30%.
  • Example 5 53 g of the volatile oil of the schizonepeta in Example 5 was mixed with microcrystalline cellulose, wherein the amount of the microcrystalline cellulose was 40% of the volatile oil of the schizonepeta, and water was added as a binder to prepare a pellet.
  • the coating conditions are as follows: water is used as the dissolving agent; the concentration of the coating liquid is 20%; the weight of the coating is 5%; the inlet air temperature is 80 ° C; the bed temperature is 45 ° C; the atomization pressure is 2.0 bar; the coating pan speed 17 rmp; feed flow rate 3 g / min.
  • Example 26 Preparation of a pill
  • Example 5 500 g of the volatile oil of the schizonepeta in Example 5 was dissolved in an appropriate amount of ethanol, 10 g of glyceryl monostearate and 50 g of sucrose were added, and the mixture was thoroughly stirred, and distilled water was added to 1000 ml, filtered, sterilized, and dispensed.
  • gelatin 100 parts of gelatin is added to 120 parts of water to cause water swelling, and 30 parts of glycerin is heated to 60 ° C, and the expanded gelatin is added, stirred, and melted to obtain a gelatin solution, which is kept for use;
  • gelatin 100 parts of gelatin is added to 140 parts of water to cause water swelling, and 30 parts of glycerin is heated to 70 ° C, and the expanded gelatin is added, stirred, and melted to obtain a gelatin solution, which is kept for use;
  • Example 1 Weigh 200g of volatile oil of Nepeta in Example 1, 350g of rapeseed salad oil, 250g of polyoxyethylene (60) castor oil, 200g of soybean lecithin, and ultrasonically to a uniform and transparent solution at 50°C to obtain raw material oil;
  • the gelatin solution and the raw material oil are put into a pellet press, and compressed into soft capsules containing 100 mg/yellow oily liquid.
  • the soft capsules are shaped, dried, washed, and sterilized, and packaged.
  • gelatin 100 parts of gelatin is added to 120 parts of water to cause water swelling, and 30 parts of sorbitol is heated to 60 ° C, and the expanded gelatin is added, stirred, and melted to obtain a gelatin solution, which is kept for use;
  • the gelatin solution and the raw material oil are placed in a pelletizer to prepare a soft capsule containing 150 mg/granule of oily liquid.
  • the soft capsule is shaped, dried, washed, and sterilized, and packaged.
  • gelatin 100 parts of gelatin is added to 130 parts of water to cause water swelling, and 30 parts of sorbitol is heated to 80 ° C, and the expanded gelatin is added, stirred, and melted to obtain a gelatin solution, which is kept for use;
  • the gelatin solution and the raw material oil are placed in a pelletizer to prepare a soft capsule containing 120 mg/granule of oily liquid.
  • the soft capsule is shaped, dried, washed, and sterilized, and packaged.
  • gelatin solution 100 parts of gelatin is added to 140 parts of water to make it absorb water, and another 35 parts of glycerin is heated to 70 ⁇ , and the expanded gelatin is added, stirred, and melted to obtain a gelatin solution, which is kept for use;
  • gelatin 100 parts of gelatin is added to 120 parts of water to cause water swelling, and 30 parts of sorbitol is heated to 80 ° C, and the expanded gelatin is added, stirred, and melted to obtain a gelatin solution, which is kept for use;
  • Example 1 Weigh 450g of the volatile oil of the schizonepeta in Example 1, 150g of water scented flower oil in Example 6, 100g of rapeseed salad oil, 50g of polyoxyethylene (35) hydrogenated castor oil, and 20g of polysorbate 80. 80 g of stearoylphosphatidylcholine, 30 g of dimyristoylphosphatidylcholine, 120 g of polyethylene glycol 4000, and ultrasonic to a uniform and transparent solution at 80 ° C to obtain a raw material oil;
  • the gelatin solution and the raw material oil are placed in a pelletizing machine to prepare a soft capsule containing 120 mg/granule of oily liquid, and the soft capsule is shaped, dried, washed, and sterilized, and packaged.
  • gelatin solution 100 parts of gelatin is added to 140 parts of water to cause water swelling, and 35 parts of glycerin is heated to 70 ° C, and the expanded gelatin is added, stirred, and melted to obtain a gelatin solution, which is kept for use;
  • gelatin solution 100 parts of gelatin is added to 140 parts of water to cause water swelling, and 35 parts of glycerin is heated to 70 ° C, and the expanded gelatin is added, stirred, and melted to obtain a gelatin solution, which is kept for use;
  • the gelatin solution and the raw material oil are placed in a pelletizing machine to prepare a soft capsule containing 120 mg/granule of oily liquid, and the soft capsule is shaped, dried, washed, and sterilized, and packaged.
  • gelatin 100 parts of gelatin is added to 140 parts of water to cause water swelling, and another 35 parts of glycerin is heated to 70 ° C, and the expanded gelatin is added, stirred, melted, and gelatin solution is obtained, and the mixture is kept for use;
  • the gelatin solution and the raw material oil are put into a pelletizing machine to prepare a soft capsule containing an oily liquid of 100 mg/granule, and the soft capsule is shaped, dried, washed, and sterilized, and packaged.
  • Example 1 Weigh 800g of volatile oil of the schizonepeta in Example 1, 150g of water scented flower oil in Example 6, 40g of rapeseed salad oil, 10g of polyoxyethylene (35) hydrogenated castor oil, and ultrasonic to 70°C to uniform and transparent The solution was poured into a hard capsule shell to prepare a capsule of 200 mg/capsule.
  • Example 2 Weigh 450g of volatile oil of Nepeta chinensis in Example 2, 150g of water scented flower oil in Example 6, 100g of rapeseed salad oil, 10g of polyoxyethylene (35) hydrogenated castor oil, 5 (TC ultrasonic to uniform, transparent The solution was poured into a hard capsule shell to prepare a capsule of 270 mg/capsule.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Description

W 一种土荆芥提取物和含有该提取物的组合物、 其制备方法与用途 技术领域
本发明涉及一种植物提取物， 具体而言， 是中药土荆芥提取物， 含有该提取 物的制剂及其制备方法； 本发明还涉及该提取物在制备治疗幽门螺旋菌引起的胃 炎、 胃溃疡药物中的应用。 背景技术
胃病是临床常见病、多发病、发病率高。 自 1983年 Marshall和 Warren在"柳 叶刀" [Warren JR, Marshall BJ. Lancet,1983,l : 1273-1275]上报告， 他们在人胃粘膜 中培养出一种螺旋状的嗜氧菌，命名为幽门螺旋菌（ Helicobacter Pylori 简称 HP )， 并证明此菌与胃炎有关后， 人们对人类上消化道疾病的认识发生了革命 （徐铃， 第一军医大学学报， 1995， 15 (4) ： 360-361 ) 。 随着研究的深入， 人们遂渐认 证幽门螺旋菌是多种胃病的发病原因。 如刘军英等报道 （刘军英， 马彩莲， 实用 医技杂志， 1998， 5 (7)： 542-544)， 同感染幽门螺旋菌有关的疾病有胃炎、 胃癌、 胃淋巴瘤、 十二指肠病等； 据国外科技动态报道 （国外科技动态， 2003， (4)： 44-45 )， 幽门螺旋菌 （HP)可引起多种胃病， 如慢性胃炎， 继而引发胃溃疡或胃 萎缩， 甚至发展成胃癌。
基于此， 人们开始研究治疗幽门螺旋菌的药物， 目前临床上应用较多的是多 种西药的组合。 如莫剑忠介绍了国外 55 组药物组合的概况 （莫剑忠， 中华消化 杂志， 1995， 15 (3 )： 164)； 黄学锐等报道了奥美拉唑和抗生素的组合 (黄学锐， 常鹤龄， 西北药学杂志， 1998， 13(1)： 33-34)。 上述西药主要是质子泵抑制剂联 用抗菌药物， 副作用大且抗生素容易产生耐药性和菌群失调。
中药以副作用低而著称， 人们对中药治疗幽门螺旋菌作用进行了筛选， 发现 敏感度较高的中药有： 黄连、 大黄、 黄柏、 蒲公英、 虎杖、 大蒜、 桂枝、 丁香等 (陈振民， 辽宁中医杂志， 1995， 22(10)： 472 )。 土荆芥为藜科植物土荆芥
Figure imgf000003_0001
ambw« cfe .）的有果穗的全草， 全草含土荆芥挥发油 0.4〜1%， 油 中主要成分为驱蛔素 （Ascaridole )、 对伞花烃 （p-Cymene) 及其他萜类物质如 土荆芥酮、 柠檬烯等； 具有祛风、 杀虫、 通经， 止痛的功能； 土荆芥在治疗幽门 杆菌引起的胃炎、 消化性胃溃疡等方面的作用未见报道。 发明内容
本发明的主要目的之一是针对现有技术的不足， 提供一种原料易得， 疗效显 著， 副作用小的土荆芥提取物。
本发明的另一目的是提供含有该提取物的组合物。
本发明的又一目的是提供含有该提取物的组合物的制备方法。
本发明还提供了该提取物及含有该提取物的组合物在制备治疗幽门螺旋菌 感染引起的胃炎、 胃溃疡药物中的应用。 本发明中使用的术语 "土荆芥提取物"也称为 "土荆芥挥发油"。
本发明通过以下技术方案予以实施。
本发明的土荆芥提取物， 通过 GC-MS分析， 所得质谱图谱中含有以下两个 峰：
峰 1 : 保留时间 8.0~9.5分钟， 碎片离子质荷比为 121， 93；
峰 2: 保留时间 9 〜 10.0分钟， 碎片离子质荷比为 120， 119， 134； 进一步地， 通过 GC-MS分析， 所得质谱图谱中还含有以下两个峰： 峰 3 : 保留时间 10.0~20.5分钟， 碎片离子质荷比为 119, 121， 136； 峰 4: 保留时间 15.0~20.5分钟， 碎片离子质荷比为 135， 43, 97。
更进一步地， 通过 GC-MS分析， 所得质谱图谱中还含有以下两个峰： 峰 5: 保留时间 5.5~15.5分钟， 碎片离子质荷比为 93， 91；
峰 6: 保留时间 12.5〜20.0分钟， 碎片离子质荷比为 71 , 126, 69， 41。
其分析条件如下：
样品制备： 将土荆芥提取物溶解在乙酸乙酯溶液中；
气相条件：
色谱柱： 为 HP— 5MS 5%P enyl Methyl Siloxane 60ηιχ0.25ηιιηχ0,25μηι弹性石 英毛细管柱；
升温程序： 从 80Ό开始， 经历 100°C， 150°C， 升温至 300°C升温程序结束； 汽化室温度： 250°C ; 载气： 高纯氦 （99.999%); 载气流速： l.OmL/分钟； 进样量： (乙酸乙酯溶液）； 分流比： 30:1 ;
质谱条件：
离子源： ΕΙ源；离子源温度： 230 °C ;四极杆温度： 150°C ;倍增器电压： 1781V; 接口温度： 280°C ; 质量扫描范围： 10-550amu。
本发明的土荆芥提取物， 以重量百分比计， 含有以下组分：
α-萜品烯 （ot-Terpinene) 15-35%, 对伞花烃 15~ 25%。
进一步地， 本发明的土荆芥提取物， 以重量百分比计， 含有以下组分- α-萜品烯 15〜35%， 对伞花烃 15~25%， 驱蛔素 10~20%， α-异松油烯 ( α-Terpinolene ) 32~40%。
更优选地， 本发明的土荆芥提取物， 以重量百分比计， 含有以下组分： a-萜品烯 20~30%， 对伞花烃 18~ 22%， 驱蛔素 12〜18%， a-异松油烯 32〜35°/0。 再优选地， 本发明的土荆芥提取物， 以重量百分比计， 含有以下组分： α-萜品烯 22~25%，对伞花烃 19~ 21%,驱蛔素 13~15%， α-异松油烯 32~33%。 还优选地， 本发明的土荆芥提取物， 以重量百分比计， 含有以下组分： α-萜品烯 15~35%，对伞花烃 15~ 25%，驱蛔素 10~20%， α-异松油烯 32~40%， γ-萜品烯 （γ-Terpinene) 0.5-0.7%, 柠檬烯 （Limonene) 0.6-0.8%；
或者， α-萜品烯 15~35%, 对伞花烃 15~ 25%， 驱蛔素 10~20%， α-异松油烯 32-40%, γ-萜品烯 0.5〜0.7%；
或者， α-萜品烯 15~35%， 对伞花烃 15~ 25%， 驱蛔素 10~20%， α-异松油烯 32-40%, 柠檬烯 0.6〜0.8%。
最佳地， 本发明的土荆芥提取物， 以重量百分比计， 含有以下组分： α-萜品烯 22~25%，对伞花烃 19~ 21%,驱蛔素 13〜15%， α-异松油烯 32~33%， γ-萜品烯 0.5〜0.6%， 柠檬烯 0.6~0.7%。
本发明还提供了含有该提取物的药物组合物， 该组合物含有如上所述的土荆 芥提取物以及药剂学可接受的辅料。
本发明提供的药物组合物还可以含有其它活性成分。 例如， 本发明提供的药 物组合物中所述的活性成分为水团花油。
本发明提供的药物组合物可以被制成各种药用制剂形式。 所述的制剂包括但 不限于胶囊剂、 硬胶囊剂、 软胶囊剂 （也称为胶丸剂）、 注射液、 滴注液、 粉针 剂、 颗粒剂、 片剂、 冲剂、 散剂、 口服液、 糖衣片剂、 薄膜衣片剂、 肠溶衣片剂、 口含剂、 丸剂、 膏剂、 丹剂、 喷雾剂、 滴丸剂、 口崩片、 微丸、 气雾剂等。
其中， 所述的胶囊剂可以是普通的胶囊剂， 也可以是以胶囊剂形式表达的自 乳化制剂。
优选地， 本发明的以土荆芥提取物为活性成分的药物组合物的制剂为胶丸 剂， 由胶丸内容物和囊材组成， 所述的胶丸内容物为土荆芥提取物和植物油。
其中所述的植物油是药剂中可接受的植物油， 如脱去固体脂肪酸的花生油、 菜籽油、 茶籽油等。
所述的土荆芥提取物和植物油的重量比为 1 :(1〜3)； 优选重量比为 1 :(1〜2)； 最佳重量比为 1 : 1。
所述的胶丸囊材包括明胶和增塑剂，其中增塑剂选自甘油、木糖醇、 山梨醇、 氢化玉米浆； 优选自甘油、 木糖醇； 最佳为甘油。
优选地， 本发明的以土荆芥提取物为活性成分的制剂制备成自乳化制剂， 所 谓自乳化制剂是乳剂形成的前体， 为包含药物、 油相、 表面活性剂和助表面活性 剂的固体或均一、 透明的液体剂型， 这一系统的基本特征是在胃肠道内或在环境 温度 (通常指体温 37Ό)及温和搅拌的情况下能自发形成水包油乳剂， 从而依靠细 小油滴的比表面积的增大而显著改善水不溶性药物在胃肠道中的溶出度， 大大增 加药物的生物利用度， 同时形成的乳剂还可减少药物对胃肠道的刺激。 可克服传 统制剂不稳定、 生物利用度低， 及其制备工艺繁琐、 服用剂量大等方面的问题。
本发明的自乳化制剂各组分重量配比为： 土荆芥提取物 1~95%， 菜籽色拉油 4〜39%， 表面活性剂 1~45%， 辅助表面活性剂 0〜15%； 优选重量配比为： 土荆芥 提取物 20~70%， 菜籽色拉油 10~30%， 表面活性剂 15〜40%， 辅助表面活性剂 5~10%。
进一步地，本发明的自乳化制剂中还可包含水团花油，其各组分重量配比为： 土荆芥提取物和水团花油 1〜95%， 菜籽色拉油 4〜39%， 表面活性剂 1〜45%， 辅助表面活性剂 0〜15%； 优选重量配比为： 土荆芥提取物和水团花油 20〜70%， 菜籽色拉油 10〜30%， 表面活性剂 15〜40%， 辅助表面活性剂 5〜10%。 其中土 荆芥挥发油和水团花油的重量比为 （1〜5 ) :1， 优选重量比为 3: 1。
所述表面活性剂选自聚氧乙烯蓖麻油缩合物、 聚氧乙烯氢化蓖麻油缩合物、 聚山梨醇酯、 磷脂等， 单独或混合使用。
所述聚氧乙烯蓖麻油缩合物为每分子中含有不同数量聚氧乙烯键的缩合物， 如： 聚氧乙烯 （35 ) 蓖麻油、 聚氧乙烯 （60) 蓖麻油等。 所述聚氧乙烯氢化蓖麻 油缩合物为每分子中含有不同数量聚氧乙烯键的缩合物， 如： 聚氧乙烯 （35 ) 氢 化蓖麻油、 聚氧乙烯 （60) 氢化蓖麻油等。 所述聚山梨醇酯优选但不局限于聚山 梨醇酯 60、 聚山梨醇酯 80。 所述磷脂来源于天然磷脂和合成磷脂， 天然磷脂包 括蛋黄卵磷脂、 大豆卵磷脂； 合成磷脂包括但不局限于二棕榈酰磷脂酰胆碱、 二 硬脂酰磷脂酰胆碱、 二肉豆蔻酰磷脂酰胆碱等。
所述助表面活性剂选自乙醇、 乙二醇、 丙二醇、 正丁醇、 异丙醇、 聚乙二醇 4000、 聚乙二醇 6000。
本发明还提供了含有土荆芥提取物的药物组合物的制备方法， 该方法包括以 下步骤：
a. 土荆芥经过常规提取方法得土荆芥提取物；
b. 加入药剂学上接受的辅料以常规制备方法制成所需制剂。
所述土荆芥提取物可以采用常规的挥发油提取方法制备， 如水蒸汽蒸馏法、 有机溶剂浸泡法（溶剂回流法）、 同时蒸馏-萃取法（SDE)、 超临界二氧化碳萃取 法、 冷榨法等； 优选水蒸气蒸馏法， 超临界二氧化碳萃取法； 最佳为水蒸气蒸馏 法。
水蒸气蒸馏法制备时， 最佳的提取步骤为： 将土荆芥种子或全草放入蒸馏锅 内， 在收集器内通蒸汽， 保持提取温度 85~100°C， 蒸馏一定时间， 例如 40分钟， 收集土荆芥挥发油。
所述水团花油可以常规的挥发油提取方法制备， 如水蒸汽蒸馏法、 有机溶剂 浸泡法 （溶剂回流法)、 同时蒸馏-萃取法 （SDE)、 超临界二氧化碳萃取法、 冷搾 法等； 优选水蒸气蒸馏法， 超临界二氧化碳萃取法； 更优选水蒸气蒸馏法； 最佳 的， 提取水团花油的步骤为： 将水团花茎叶放入蒸馏锅内， 在收集器内通蒸汽， 保持提取温度 85~100°C， 蒸馏一定时间， 例如 40分钟， 收集挥发油。
也可将土荆芥和水团花放在一起以常规的挥发油提取方法提取， 如水蒸汽蒸 馏法、 有机溶剂浸泡法（溶剂回流法)、 同时蒸馏-萃取法（SDE)、 超临界二氧化 碳萃取法、 冷榨法等； 优选水蒸气蒸馏法， 超临界二氧化碳萃取法； 更优选水蒸 气蒸馏法； 最佳的， 提取的步骤为： 将土荆芥种子或全草和水团花茎叶放入蒸馏 锅内， 在收集器内通蒸汽， 保持提取温度 85~100°C， 蒸馏一定时间， 例如 40分 钟， 收集挥发油。
本发明的药物组合物的制备方法， 其中所制备的组合物是胶丸， 该制备方法 包括取药用明胶和增塑剂， 于蒸馏水中溶解过滤， 制成明胶溶液； 用植物油溶解 稀释土荆芥挥发油， 得原料油； 将原料油与明胶溶液加入胶丸生产设备中制成内 含油状液体的胶丸。
其中所述的增塑剂选自甘油、 木糖醇、 山梨醇和氢化玉米浆。
本发明的药物组合物的制备方法， 其中所制备的组合物是自乳化制剂， 该制 备方法包括按处方量称取土荆芥提取物土荆芥提取物和水团花油、 菜籽色拉油、 表面活性剂或者再加上助表面活性剂， 30〜80°C水浴加热或者超声至均一、 透明 的溶液， 再制备成软胶囊或者硬胶囊制剂。
上述自乳化制剂的药物组合物的制备方法中所述表面活性剂选自聚氧乙烯 蓖麻油缩合物、 聚氧乙烯氢化蓖麻油缩合物、 聚山梨醇酯、 磷脂。
进一步的， 上述自乳化制剂的药物组合物的制备方法中所述聚氧乙烯蓖麻油 縮合物选自聚氧乙烯 （35 ) 蓖麻油、 聚氧乙烯 （60) 蓖麻油； 所述聚氧乙烯氢化 蓖麻油缩合物选自聚氧乙烯 （35 ) 氢化蓖麻油、 聚氧乙烯 （60 ) 氢化蓖麻油； 所 述聚山梨醇酯选自聚山梨醇酯 60、 聚山梨醇酯 80; 所述磷脂选自蛋黄卵磷脂、 大豆卵磷脂、 二棕榈酰磷脂酰胆碱、 二硬脂酰磷脂酰胆碱、 二肉豆蔻酰磷脂酰胆 碱。 所述的助表面活性剂选自乙醇、 乙二醇、 丙二醇、 正丁醇、 异丙醇、 聚乙二 醇 4000、 聚乙二醇 6000。
本发明的土荆芥提取物以及含有该提取物的组合物可用于治疗幽门螺旋菌感 染引起的胃炎、 消化性溃疡等胃病。
本发明以中药土荆芥为原料提取其有效成分用于幽门螺旋菌感染引起的胃 炎、 消化性溃疡等胃病， 材料易得， 生产工艺简单、 易行、 容易控制质量； 疗效 显著， 副作用小且使用方便。进一步采用的自乳化制剂具有靶向性， 更易于吸收， 从而增加生物利用度； 同时可减轻患者的不良反应， 且避免了水分、 氧等不稳定 因素的影响， 从而增强了药物的稳定性。
附图说明
图 1 中国福建产土荆芥的挥发油总离子流图
图 2 中国湖南产土荆芥的挥发油总离子流图 图 3 中国陕西产土荆芥的挥发油总离子流图
图 4 α-萜品烯质谱图
图 5 对伞花烃质谱图
图 6 α-异松油烯质谱图
图 7 驱蛔素质谱图
以下通过试验例来进一步阐述本发明， 但不以任何形式对本发明构成限制。 试验例一 土荆芥挥发油的 GC/MS分析
1. 土荆芥挥发油的提取
1.1. 药材
药材为新采集的福建产土荆芥， 经天津天士力制药股份有限公司质检部鉴定 为藜科藜属植物土荆芥。 湖南、 陕西产土荆芥由天津天士力制药股份有限公司湖 南及陕西药材种植基地提供。
1.2. 提取方法
将土荆芥全草鲜品 300g， 切碎， 常压水蒸汽蒸馏， 收集馏出液， 直到没有油 滴馏出为止， 分取上面的油层， 用无水硫酸钠干燥， 得到具有特殊气味的浅黄色 挥发油约 2.2mL， 得油率约为 0.75%。
2. 仪器与试药
2.1. 仪器
气质联用仪为 HP6890/HP5973 GC/MS联用仪 （美国安捷伦公司）。
2.2. 试药
乙酸乙酯 （分析纯， 天津市化学试剂二厂）； 无水硫酸钠 （分析纯， 天津市 化学试剂二厂）； 去离子水 （天士力制药股份有限公司制水车间制造）。
3. 色谱条件
3.1. 气相条件
色谱柱： 为 HP— 5MS 5%Phenyl Methyl Siloxane 60πιχ0.25πιπιχ0·25μπι弹性石 英毛细管柱；
升温程序： 从 80°C开始， 在 80°C保持 10分钟， 4Ό/分钟升温至 100°C并保持 5 分钟， 以 5°C/分钟升温至 150°C并保持 5分钟， 然后以 20°C/分钟升温至 300°C并保 持 2.5分钟， 升温程序结束；
汽化室温度： 250Ό ; 载气： 高纯氦 （99.999%); 载气流速： l.OmL/分钟； 进样量： (乙酸乙酯溶液）； 分流比： 30:1。 3.2. 质谱条件
离子源： EI源； 离子源温度： 230 °C ; 四极杆温度： 15CTC ; 电子能量： 70ev; 发射电流： 34.6UA; 倍增器电压： 1781V; 接口温度： 280°C ; 质量扫描范围： 10-550amu。
4. 实验步骤
4.1. 定性分析
取土荆芥挥发油的乙酸乙酯溶液 ΙμΙ^, 用气相色谱-质谱联用仪分析鉴定， 从 总离子流图中共检测出 70个色谱峰， 通过 HP MSD化学工作站检索 Nist98标准 质谱图库， 并结合相关文献， 确认了 33种成分。
4.2. 挥发油中各组分的比例
通过 HP MSD化学工作站数据处理系统， 按峰面积归一化法进行计算， 求得 各化学成分在挥发油中的相对百分含量。
5. 实验结果
按照上述实验条件和步骤， 所得福建、 湖南、 陕西产土荆芥的挥发油总离子 流图见图 1-图 3， 共有组分鉴定结果见表 1。
表 1 土荆芥挥发油成分鉴定结果
编号 英文名称 分子式 CAS 化学结构 相对含 量 （％)
1 2-pinene 2-蒎烯 C10H16 80-56-8 0.063%
2 Pinene 蒎烯 C10H16 127-91-3 0.043%
Figure imgf000009_0001
3 myrcene 月桂烯 C10H16 123-35-3 0.064%
4 3-carene 3-蒈烯 C10H16 13466-78-9 0.080%
5 Alpha-terpinene α-萜品烯 C10H16 99-86-5 24.418%
Figure imgf000009_0002
6 p-cymene 对伞花烃 C10H14 99-87-6 20.142%
7 (+) -(R)-limonene 柠檬烯 C10H16 5989-27-5 0.677%
8 Gamma. -Terpinen γ-萜品烯 C10H16 99-85-4 0.595%
9 p-Isopropenyl 对异丙烯基 C10H12 1195-32-0 0.188% toluene 妥路香
10 3 ,4-dimethylphen 3， 4-二甲基 CioH140 2219-78-5 0.059% ol, 6-Ethyl- -6-乙基苯
Figure imgf000009_0003
酚 t > ) t tsJ tsJ t to t
7%195 0.0 CH A t
gyiateul tlhtoi Is ¾%py5¾5y 0.17445 8 Cnehlleor Ca-- %。72一.0 00 15186 C10alenar 3C--- %y¾6l7 0.073115 21dealdehiller p-- - ¾w。i7%l78 14. 585612H Cdoleari Asc-- 14yS7%8 0.28 89830 CHolhmT m--- i6¾。0%8 0.56384 528H<--
Figure imgf000010_0001
70% 0.49997 572-- Sie.83% 32498662 5H--
〕|i5.1.02- 4¾"i¾l 073%.179530584 C-- SI% 0.1389707i C 11H-- ¾附- # ®K3 -- nI8% 0.0375575 CH
0.043% 99325-- 禁0 P 0.18%255151 251H-- i。9%9 0.01955115 CH 2-- 塞SM% 0.4295048 C〇 52H-- 4辦yIQIe186% 1 0.000 C 72124Ho。1en 1clohex 2C ---- ---
Ύ ® 1一 29 Precocene I 早熟素 I C12H1402 17598-02-6
Figure imgf000011_0001
、
Figure imgf000011_0002
试验例二 土荆芥挥发油药效学试验
实验材料
1. 受试药：
土荆芥挥发油： 按照实施例 5的方法制备， 黄色油状物， 生产批号： 20040129， 由天津天士力制药股份有限公司提供， 容量瓶密闭保存， 临用前用植物油稀释配 成所需浓度， 供动物灌胃 （ig) 给药。
2. 阳性对照药：
雷尼替丁： 石家庄四药股份有限公司生产， 批号： 030836。
3. 试剂：
3.1 植物油： 福临门天然谷物调和油， 市售， 生产批号： 03110405。
3.2 乙酸： 天津市天河化学试剂厂生产， 批号： 20030722。
3.3 2%印度墨汁： 北京市西中化工厂生产， 批号 980301。 加 5%阿拉伯胶溶液配 成。
3.4幽门螺旋杆菌菌株： 国际标准菌株 26695。
3.5培养基： 哥伦比亚琼脂培养基 （Columbia agar base), 原产国， Oxoid, 英国.
3.6抗生素： 盐酸万古霉素， 多粘菌素 B， 两性霉素 B， Sigma公司产品。
3.7混合气（5 %氧气、 10%CO2、 85 %N2) : 北京普来克斯实用气体有限公司提供。
4. 实验动物
1. Km种小鼠， 体重 18-22 (g)， 雌雄各半。
2. Wistar种大鼠， 体重 160-220 (g), 雌雄各半。
由天津药物研究院动物室生产提供，合格证号： W-J津实动质 R准字 001号。 上述动物均饲养在有中央空调的观察室 （津实设施准第 012号， 符合屏障级 标准） 中。 大、 小鼠喂词专用全价营养块料 （天津市华荣实验动物科技有限公司 生产）， 饮自来水。
试验方法和结果
1. 对乙酸烧灼致大鼠胃溃疡的影响 分 本试验选用 Wistar大鼠 80只， 雌雄各半， 体重 200— 220g， 随机分为 8组， 组
每组 10只。 按表 2所示剂量 ig给药， 每天 1次， 连续 13天， 模型对照组 ig给 予同体积的植物油。 于第 3次给药后 2小时进行造模。 造模前禁食 24小时， 动 物乙醚麻醉， 腹部剃毛消毒， 剑突下沿正中线切一小口， 将胃轻轻拉出， 于近幽 门腺胃部桨膜下注射 40%乙酸 10μ1， 将胃送回腹腔， 缝合伤口。 术后继续给药。 于末次给药后禁食高中 24 小时， 乌拉坦麻醉处死动物， 剖开腹腔， 取出整个胃， 沿 胃大弯剖开， 用生理齐盐水冲洗内容物后， 1 %甲醛固定 10分钟， 用精密卡尺测量 溃疡点的直径， 计算溃疡面积； 用微量注射器向溃疡处注入墨汁至胃粘膜表面水 平， 记录注入墨汁的体积， 以溃疡点的面积及注入墨汁的体积表示溃疡的程度。 结果 （见表 2 ) 显示， 土荆芥挥发油样品组动物的溃疡面积均缩小， 注入的墨汁 体积亦减少， 表明药物有显著的促进溃疡愈合的作用。
表 2 土荆芥挥发油对乙酸烧灼型胃溃疡的影响 （ ± 1)， η= 10 )
剂量 溃疡面积 溃疡区注入墨
(mg/kg) (mm2) 汁的体积 (μΐ) 模型对照组 24.52±11.29 7.74士 3.83 雷尼替丁 8,08±5.72** 2.85±2.63** 土荆芥挥发油 10.57±5.45** 3.25±1.24**
8.93±6.64* * 2.27±1.84**
Figure imgf000012_0001
8.71士 5.41 ** 1.67±1.29*** 与模型对照组比较 *ρ<0.05 **ρ<0.01 ***ρ<0.001
2. 对大鼠幽门结扎型胃溃疡的影响
本试验选用 Wistar大鼠 80只， 雌雄各半， 体重 160g左右， 随机分为 8组， 每组 10只。 按表 3所示剂量 ig给药， 每天 1次， 连续 3天， 模型对照组 ig给予 同体积植物油。于末次给药后 2小时（给药前动物禁食 48小时）， 乙醚麻醉动物， 腹部剃毛消毒， 剑突下切一小口， 将胃轻轻拉出， 结扎幽门后将胃送回腹腔， 缝 合伤口。 术后禁食禁水 6小时， 麻醉处死动物， 剖开腹部， 结扎贲门， 取出整个 胃， 沿胃大弯剖开， 生理盐水冲净内容物后， 1 %甲醛固定 10分钟， 用精密卡尺 测量溃疡点的直径， 以每只大鼠各溃疡点的面积之和， 表示溃疡大小， 按 Okabe 法将溃疡面积总和分为 5个等级， 作为溃疡指数。 结果 （见表 3 ) 显示， 给药组 溃疡指数均显著低于模型对照组， 表明土荆芥挥发油能够显著地抑制幽门结扎型 胃溃疡的形成。
表 3. 土荆芥挥发油对幽门结扎型胃溃疡的影响 ± S ， n= 10 )
剂量 （mg/kg)
模型对照组 2.7±1.8
雷尼替丁 2- 0.8±0.6**
土荆芥挥发油 0.9士 0.6*
0 1.0±0.8*
Figure imgf000012_0002
注： 溃疡指数判定标准：
溃疡指数 1 2 3 4 5
溃疡面积 （mm2) 1〜12 13〜25 26〜37 38〜50 ≥50或胃穿孔 面积小于 1mm2溃疡点， 10个相当溃疡面积 1mm2
3. 对小鼠肠推进运动的影响
高低中
试验选用 Km种剂剂剂小鼠 80只， 体重 18— 22(g), 雌雄各半， 随机分组， 每组 10 只。 按表 4所示剂量分别 ig给药， 每天 1次， 连续 3天， 对照组 ig给予同体积 的植物油。 于末次给药 （给药前动物禁食 24小时） 后 40分钟， 各组动物灌胃给 予浓度为 2 %的印度墨汁 (用 5 %阿拉伯胶溶液配制)，对照组 ig给予同体积 5 %阿 拉伯胶溶液。 20分钟后脱颈处死小鼠，剖开腹部，轻轻取出并分离整个胃及小肠， 平铺于蜡板上， 测量幽门到回盲部的长度， 为小肠全长， 再测量幽门到墨汁推进 前沿的长度为小肠推进长度。 以小肠推进长度比上小肠全长计算推进百分率， 将 各给药组动物的平均推进百分率与对照组平均推进百分率进行统计学 t检验。 结 果 （见表 4 ) 显示， 土荆芥挥发油高、 中剂量的肠推进百分率显著低于对照组， 表明药物有明显的抑制肠运动功能。
表 4. 土荆芥挥发油对小鼠肠推进运动的影响 （ ± S ， n= 10 )
1 剂量 （mg/kg) 墨汁推进百分率 ± S % ) 对照组 - 49.25±5.82
阿托品 15 25.51±10.92*** 土荆芥挥发油 20 32.73±16.41 *
10 31.30±20.11*
5 30.47±27.04
与对照组比较 *p<0.05 ***p<0.001
4. 对幽门螺旋杆菌体外抑制试验
菌株： 国际标准菌株 26695
培养基的制备： 3.9g哥伦比亚琼脂培养基 （Columbia agar base ) , 加入 100ml水, 15磅 20分钟高压， 待冷却至 50°C时， 无菌条件下加入 7ml脱纤维羊血， 2ml抗 生素。
混合气培养条件： 5%O2、 10 % CO2、 85 %N2混合气， 37°C恒温。
药物用蛋黄研磨成乳化液，高压灭菌后倍比稀释混入培养基中，每皿加入 100 μΐ制备好的菌液， 涂匀， 经 37°C微厌氧菌环境培养 72小时后观察结果， 无 HP 生长的培养皿中的药物浓度为土荆芥挥发油对 HP的最低抑菌浓度。 结果 （见表 5 ) 显示， 土荆芥挥发油样品的最低抑菌浓度均为 0.097mg/ml， 表明对幽门螺旋 杆菌均有显著的抑制作用。 表 5. 土荆芥挥发油对体外幽门螺旋杆菌的抑制作用
. 药物浓度 （mg/ml)
药物
24.8 12.4 6.2 3.1 1.55 0.78 0.39 0.194 0.097 0.048 0.024 0.012 0 土荆芥挥发油 ++ ++ ++
"++"为平行样， 均有 HP菌生长
"一一 "为平行样均未见 HP菌生长
试验结论
以上四个试验表明， 本发明土荆芥挥发油对乙酸烧灼型胃溃疡有非常显著的 促愈合作用； 对幽门结扎型胃溃疡的形成有显著的抑制作用； 对小鼠肠推进运动 有显著抑制； 对体外幽门螺旋杆菌的生长有明显的抑制。
具体实施方式 _
以下通过具体实施方式来进一步说明本发明的保护范圉， 但以下实施例不以 任何方式对本发明构成限制。
需要说明的是， 下列实施例中所述的比例均为重量比， 所述的份数均为重量 份数。
实施例 1 土荆芥挥发油的制备
称取土荆芥全草 1000g于萃取槽中，调节萃取温度为 35 °C，压力为 30Mpa, 提 取 5h， CO2流量为 5L/ (kg药材，小时）， CO2超临界流体萃取得挥发油 5g。 实施例 2 土荆芥挥发油的制备
称取土荆芥全草 1000g于萃取槽中，调节萃取温度为 48°C，压力为 30Mpa, 提 取 8h， CO2流量为 7L/ (kg药材 *小时）， CO2超临界流体萃取得挥发油 4.6g。 实施例 3 土荆芥挥发油的制备
称取土荆芥全草 1000g放入蒸馏锅内， 在收集器内通蒸气， 保持提取温度 85 °C， 蒸馏 40分钟， 收集挥发油 4.8g。
实施例 4 土荆芥挥发油的制备
称取土荆芥全草 1000g放入蒸馏锅内， 在收集器内通蒸气， 保持提取温度 95 V , 蒸馏 40分钟， 收集挥发油 5.2g。
实施例 5 土荆芥挥发油的制备
称取土荆芥全草 1000g放入蒸馏锅内， 在收集器内通蒸气， 保持提取温度 90 °C , 蒸馏 40分钟， 收集挥发油 4.5g。
实施例 6 水团花油的制备
称取水团花茎叶 1000g放入蒸馏锅内， 在收集器内通蒸气， 保持提取温度 95 °C， 蒸馏 40分钟， 收集挥发油 5.5g。
实施例 7 水团花油的制备
称取水团花茎叶 1000g放入萃取槽内，调节萃取温度为 35Ό，压力为 30Mpa, 提取 4h， CO2流量为 5L/ (kg药材，小时）， CO2超临界流体萃取得挥发油 5.5g。 实施例 8 土荆芥挥发油和水团花油的制备
称取土荆芥全草 600g，水团花茎叶 400g于萃取槽中，调节萃取温度为 35°C， 压力为 30Mpa, 提取 5h， C02流量为 5L/ (kg药材，小时）， CO2超临界流体萃取 得挥发油 10.3g。
实施例 9 土荆芥挥发油和水团花油的制备
称取土荆芥全草 500g，水团花茎叶 500g放入蒸馏锅内， 在收集器内通蒸气， 保持提取温度 85 °C， 蒸镏 40分钟， 收集挥发油 9.8g。
实施例 10 胶丸的制备
取明胶 100份加入 120份水中使其吸水膨胀， 另将 30份甘油加热至 60°C， 将膨胀的明胶加入， 搅拌， 熔融， 得明胶溶液， 保温待用；
取实施例 1制备的土荆芥挥发油， 加入植物油， 植物油与土荆芥挥发油的重 量比为 3: 1 ; 搅匀， 得原料油；
将明胶溶液与原料油装入自动旋转轧囊机，压制成内含油状液体 lOOmg/粒的 胶丸， 胶丸定型、 干燥、 洗涤、 消毒， 包装即得。
实施例 11 胶丸的制备
取明胶 100份加入 140份水中使其吸水膨胀， 另将 30份甘油加热至 70°C， 将膨胀的明胶加入， 搅拌， 熔融， 得明胶溶液， 保温待用；
取实施例 2制备的土荆芥挥发油， 加入植物油， 植物油与土荆芥挥发油的重 量比为 2:1 ; 搅匀， 得原料油；
将明胶溶液与原料油装入自动旋转轧囊机， 压制成内含油状液体 90mg/粒的 胶丸， 胶丸定型、 干燥、 洗涤、 消毒， 包装即得。
实施例 12 胶丸的制备
取明胶 100份加入 130份水中使其吸水膨胀， 另将 30份甘油加热至 80°C， 将膨胀的明胶加入， 搅拌， 熔融， 得明胶溶液， 保温待用；
取实施例 3制备的土荆芥挥发油， 加入植物油， 植物油与土荆芥挥发油的重 量比为 1.5: 1 ; 搅匀， 得原料油；
将明胶溶液与原料油装入滴丸机制成内含油状液体 90mg/粒的胶丸， 胶丸定 型、 干燥、 洗涤、 消毒， 包装即得。
实施例 13 胶丸的制备 取明胶 100份加入 140份水中使其吸水膨胀， 另将 35份甘油加热至 70Ό， 将膨胀的明胶加入， 搅拌， 熔融， 得明胶溶液， 保温待用；
取实施例 5制备的土荆芥挥发油， 加入植物油， 植物油同土荆芥挥发油的重 量比为 1 : 1 ; 搅匀， 得原料油；
将明胶溶液与原料油装入滴丸机制成内含油状液体 80mg/粒的胶丸， 胶丸定 型、 干燥、 洗涤、 消毒， 包装即得。
施例 14胶丸的制备
取明胶 100份加入 120份水中使其吸水膨胀，另将 40份木糖醇加热至 80Ό， 将膨胀的明胶加入， 搅拌， 熔融， 得明胶溶液， 保温待用；
取实施例 4制备的土荆芥挥发油， 加入植物油， 植物油与土荆芥挥发油的重 量比为 1 : 1 ; 搅匀， 得原料油；
将明胶溶液与原料油装入滴丸机制成内含油状液体 80mg/粒的胶丸， 胶丸定 型、 干燥、 洗涤、 消毒， 包装即得。
实施例 15 胶丸的制备
取明胶 100份加入 120份水中使其吸水膨胀， 另将 30份甘油加热至 60Ό， 将膨胀的明胶加入， 搅拌， 熔融， 得明胶溶液， 保温待用；
取实施例 5制备的土荆芥挥发油， 加入植物油， 植物油与土荆芥挥发油的重 量比为 1.1 : 1 ; 搅匀， 得原料油；
将明胶溶液与原料油装入滴丸机制成内含油状液体 80mg/粒的胶丸， 胶丸定 型、 干燥、 洗涤、 消毒， 包装即得。
实施例 16胶丸的制备
取明胶 100份加入 120份水中使其吸水膨胀，另将 30份山梨醇加热至 80°C , 将膨胀的明胶加入， 搅拌， 熔融， 得明胶溶液， 保温待用；
取实施例 5制备的土荆芥挥发油， 加入植物油， 植物油与土荆芥挥发油的重 量比为 1.3: 1 ; 搅匀， 得原料油；
•将明胶溶液与原料油装入软胶囊生产灌装机， 制成内含油状液体 80mg/粒的 胶丸， 胶丸定型、 干燥、 洗涤、 消毒， 包装即得。
实施例 17 胶丸的制备
取明胶 100份加入 110份水中使其吸水膨胀， 另将 40份氢化玉米浆加热至 80°C , 将膨胀的明胶加入， 搅拌， 熔融， 得明胶溶液， 保温待用；
取实施例 5制备的土荆芥挥发油， 加入植物油， 植物油与土荆芥挥发油的重 量比为 2.5: 1 ; 搅匀， 得原料油；
将明胶溶液与原料油装入转模式胶丸制造机， 制成内含油状液体 90mg/粒的 胶丸， 胶丸定型、 干燥、 洗涤、 消毒， 包装即得。
实施例 18 胶丸的制备
取明胶 100份加入 140份水中使其吸水膨胀， 另将 30份甘油加热至 70°C， 将膨胀的明胶加入， 搅拌， 熔融， 得明胶溶液， 保温待用；
取实施例 2制备的土荆芥挥发油， 加入植物油， 植物油与土荆芥挥发油的重 量比为 1:1， 用剪切式乳匀机剪切至适宜的分散度， 得原料油；
将明胶溶液与原料油装入转模式胶丸制造机，制成内含油状液体 120mg/粒的 胶丸， 胶丸定型、 干燥、 洗涤、 消毒， 包装即得。
实施例 19 胶丸的制备
取明胶 100份加入 120份水中使其吸水膨胀，另将 30份山梨醇加热至 60°C， 将膨胀的明胶加入， 搅拌， 熔融， 得明胶溶液， 保温待用；
取实施例 5制备的土荆芥挥发油， 加入植物油， 植物油与土荆芥挥发油的重 量比为 2:1， 用剪切式乳匀机剪切至适宜的分散度， 得原料油；
将明胶溶液与原料油装入滴丸机制成内含油状液体 150mg/粒的胶丸，胶丸定 型、 干燥、 洗涤、 消毒， 包装即得。
实施例 20 胶丸的制备
取明胶 100份加入 130份水中使其吸水膨胀， 另将 30份甘油加热至 70V , 将膨胀的明胶加入， 搅拌， 熔融， 得明胶溶液， 保温待用；
取实施例 4制备的土荆芥挥发油， 加入植物油， 植物油与土荆芥挥发油的重 量比为 2.5:1， 用剪切式乳匀机剪切至适宜的分散度， 得原料油；
将明胶溶液与原料油装入滴丸机制成内含油状液体 140mg/粒的胶丸，胶丸定 型、 干燥、 洗涤、 消毒， 包装即得。
实施例 21 片剂的制备
将实施例 1中的土荆芥挥发油 56g与淀粉 1 : 1 比例混合， 将 25g羧甲基纤 维素钠与上述混合物混合均匀， 加入 75%的乙醇溶液作为粘合剂， 过 22 目筛， 40°C烘箱干燥， 加入适量硬脂酸镁， 压片， 制成 300mg/片的片剂。
实施例 22包衣片剂的制备
将实施例 4中的土荆芥挥发袖 53g与 17g轻质氧化镁混合， 加入 17g淀粉， 乳糖 17g， 0.5%的 HPMC水溶液做粘合剂， 制成 300mg/片的素片， 以 30%的尤 特奇 RL30D包衣， 制成 300mg/片的包衣制剂。
实施例 23胶囊的制备
将实施例 3中的土荆芥挥发油 52g与淀粉 1 : 1 比例混合， 将 25g羧甲基纤 维素钠与上述混合物混合均匀， 加入 75%的乙醇溶液作为粘合剂， 过 22 目筛， 40°C烘箱干燥， 整粒， 装硬胶囊， 制成 270mg/粒的胶囊。
实施例 24浓缩丸的制备
将实施例 5中的土荆芥挥发油 53g与微晶纤维素进行混合， 其中微晶纤维素 的用量为土荆芥挥发油的 40%， 加入水作为粘合剂制成素丸。
将上述素丸选用上海卡乐康（COLORCON)包衣技术有限公司的欧巴代（胃 溶型） 为本品的包衣材料进行包衣， 得浓缩丸制剂。
包衣条件如下： 选用水为溶解剂； 包衣液浓度为 20%; 包衣增重 5%; 进风 温度 80°C； 片床温度 45°C； 雾化压力 2.0bar; 包衣锅转速 17rmp; 进料流速 3g/ 分钟。
实施例 25 颗粒剂的制备
取实施例 5中的土荆芥挥发油 53g， 甲基纤维素 9g,糖粉 820g，混合均匀后， 加入适量 70%乙醇， 制成软材， 制粒， 挥去乙醇， 80°C喷雾干燥， 制成颗粒剂。 实施例 26 滴丸剂的制备
取 300g聚乙二醇 6000加热至 80°C，熔融后加入实施例 3中的土荆芥挥发油 50g， 搅拌均匀， 移至滴丸机中， 保持熔融液温度 70°C， 由上往下， 滴速适中滴 入 10°C甲基硅油中， 制成滴丸剂。
实施例 27 滴丸剂的制备
取 300g聚乙二醇 4000加热至 75°C，熔融后加入实施例 5中的土荆芥挥发油 53g, 搅拌均匀， 移至滴丸机中， 保持熔融液温度 65°C， 由上往下， 滴速适中滴 入 0Ό液体石蜡中， 制成滴丸剂。
实施例 28 滴丸剂的制备
取 300g聚乙二醇 4000加热至 90°C，熔融后加入实施例 1中的土荆芥挥发油 60g, 搅拌均匀， 移至滴丸机中， 保持熔融液温度 80°C， 由上往下， 滴速适中滴 入 4°C液体石蜡中， 制成滴丸剂。
实施例 29 口服液的制备
将实施例 5中的土荆芥挥发油 500g溶解在适量乙醇中， 加入单硬脂酸甘油 酯 10g， 蔗糖 50g， 充分搅拌均匀， 加入蒸馏水至 1000ml, 过滤， 灭菌， 分装， 即得。
实施例 30 土荆芥提取物自乳化软胶囊的制备
取明胶 100份加入 120份水中使其吸水膨胀， 另将 30份甘油加热至 60°C， 将膨胀的明胶加入， 搅拌， 熔融， 得明胶溶液， 保温待用；
称取实施例 1中的土荆芥挥发油 10g， 菜籽色拉油 390g， 聚氧乙烯 （35 ) 蓖 麻油 500g， 乙二醇 100g， 30°C水浴加热为均一、 透明的溶液， 得原料油； 将明胶溶液与原料油装入压丸机， 压制成内含油状液体 lOOmg/粒的软胶囊， 软胶囊定型、 干燥、 洗涤、 消毒， 包装即得。
实施例 31 土荆芥提取物自乳化软胶囊的制备
取明胶 100份加入 140份水中使其吸水膨胀， 另将 30份甘油加热至 70°C， 将膨胀的明胶加入， 搅拌， 熔融， 得明胶溶液， 保温待用；
称取实施例 1 中的土荆芥挥发油 200g， 菜籽色拉油 350g， 聚氧乙烯 （60) 蓖麻油 250g, 大豆卵磷脂 200g, 50°C超声至均一、 透明的溶液， 得原料油； 将明胶溶液与原料油装入压丸机， 压制成内含油状液体 lOOmg/粒的软胶囊， 软胶囊定型、 干燥、 洗涤、 消毒， 包装即得。
实施例 32 土荆芥提取物自乳化软胶囊的制备
取明胶 100份加入 120份水中使其吸水膨胀，另将 30份山梨醇加热至 60°C， 将膨胀的明胶加入， 搅拌， 熔融， 得明胶溶液， 保温待用；
称取实施例 2中的土荆芥挥发油 275g， 菜籽色拉油 325g， 聚氧乙烯 （60 ) 蓖麻油 300g， 蛋黄卵磷脂 50g， 丙二醇 50g， 60°C水浴加热为均一、 透明的溶液， 得原料油；
将明胶溶液与原料油装入压丸机， 制成内含油状液体 150mg/粒的软胶囊， 软 胶囊定型、 干燥、 洗涤、 消毒， 包装即得。
实施例 33 土荆芥提取物自乳化软胶囊的制备
取明胶 100份加入 130份水中使其吸水膨胀，另将 30份山梨醇加热至 80°C， 将膨胀的明胶加入， 搅拌， 熔融， 得明胶溶液， 保温待用；
称取实施例 3中的土荆芥挥发油 600g， 菜籽色拉油 100g， 聚氧乙烯 （35 ) 氢化蓖麻油 50g， 聚山梨醇酯 80为 20g， 二硬脂酰磷脂酰胆碱 80g， 二肉豆蔻酰 磷脂酰胆碱 30g， 聚乙二醇 4000为 120g， 80°C超声至均一、 透明的溶液， 得原 料油；
将明胶溶液与原料油装入压丸机， 制成内含油状液体 120mg/粒的软胶囊， 软 胶囊定型、 干燥、 洗涤、 消毒， 包装即得。
实施例 34 土荆芥提取物自乳化软胶囊的制备
取明胶 100份加入 140份水中使其吸水膨胀， 另将 35份甘油加热至 70Ό， 将膨胀的明胶加入， 搅拌， 熔融， 得明胶溶液， 保温待用；
称取实施例 3中的土荆芥挥发油 735g， 菜籽色拉油 65g， 聚山梨醇酯 60为 50g， 聚氧乙烯 （60 ) 氢化蓖麻油 150g， 70°C超声至均一、 透明的溶液， 得原料 油；
将明胶溶液与原料油装入压丸机，制成内含油状液体 150mg/粒的软胶囊，软 胶囊定型、 干燥、 洗涤、 消毒， 包装即得。 实施例 35 土荆芥提取物自乳化硬胶囊的制备
称取实施例 2中的土荆芥挥发油 950g， 菜籽色拉油 50g， 聚氧乙烯 （35 ) 氢 化蓖麻油 20g， 70Ό超声至均一、 透明的溶液， 灌入硬胶囊壳， 制成 270mg/粒的 胶囊。
实施例 36 土荆芥提取物自乳化硬胶囊的制备
称取实施例 2中的土荆芥挥发油 950g， 菜籽色拉油 40g， 聚氧乙烯 （60 ) 氢 化蓖麻油 30g， 异丙醇 80g， 30°C超声至均一、 透明的溶液， 灌入硬胶囊壳， 制 成 300mg/粒的胶囊。
实施例 37 土荆芥提取物自乳化硬胶囊的制备
称取实施例 1中的土荆芥挥发油 960g， 菜籽色拉油 40g， 聚氧乙烯 （35 ) 氢 化蓖麻油 15g， 70°C超声至均一、 透明的溶液， 灌入硬胶囊壳， 制成 200mg/粒的 胶囊。
实施例 38 土荆芥提取物自乳化硬胶囊的制备
称取实施例 5中的土荆芥挥发油 335g， 菜籽色拉油 365g， 聚山梨醇酯 80为 150g， 大豆卵磷脂 150g， 80°C水浴加热为均一、 透明的溶液， 灌入硬胶囊壳， 制 成 270mg/粒的胶囊。
实施例 39土荆芥挥发油和水团花油自乳化软胶囊的制备
取明胶 100份加入 120份水中使其吸水膨胀，另将 30份山梨醇加热至 80°C， 将膨胀的明胶加入， 搅拌， 熔融， 得明胶溶液， 保温待用；
称取实施例 1 中的土荆芥挥发油 450g， 实施例 6中的水团花油 150g， 菜籽 色拉油 100g， 聚氧乙烯 （35 )氢化蓖麻油 50g， 聚山梨醇酯 80为 20g， 二硬脂酰 磷脂酰胆碱 80g， 二肉豆蔻酰磷脂酰胆碱 30g， 聚乙二醇 4000为 120g， 80°C超声 至均一、 透明的溶液， 得原料油；
将明胶溶液与原料油装入压丸机，制成内含油状液体 120mg/粒的软胶囊，软 胶囊定型、 干燥、 洗涤、 消毒， 包装即得。
实施例 40 土荆芥挥发油和水团花油自乳化软胶囊的制备
取明胶 100份加入 140份水中使其吸水膨胀， 另将 35份甘油加热至 70°C， 将膨胀的明胶加入， 搅拌， 熔融， 得明胶溶液， 保温待用；
称取实施例 3中的土荆芥挥发油 335g， 实施例 6中的水团花油 365g， 菜籽 色拉油 100g， 聚氧乙烯 （60)氢化蓖麻油 10g， 聚山梨醇酯 80为 20g， 二硬脂酰 磷脂酰胆碱 80g， 聚乙二醇 4000为 120g， 60°C超声至均一、 透明的溶液， 得原 料油；
将明胶溶液与原料油装入压丸机，制成内含油状液体 150mg/粒的软胶囊，软 胶囊定型、 干燥、 洗涤、 消毒， 包装即得。 实施例 41 土荆芥挥发油和水团花油自乳化软胶囊的制备
取明胶 100份加入 140份水中使其吸水膨胀， 另将 35份甘油加热至 70°C， 将膨胀的明胶加入， 搅拌， 熔融， 得明胶溶液， 保温待用；
称取实施例 2中的土荆芥挥发油 490g， 实施例 7中的水团花油 245g， 菜籽 色拉油 65g， 聚山梨醇酯 60为 50g， 聚氧乙烯（60 )氢化蓖麻油 150g， 7(TC超声 至均一、 透明的溶液， 得原料油；
将明胶溶液与原料油装入压丸机，制成内含油状液体 120mg/粒的软胶囊，软 胶囊定型、 干燥、 洗涤、 消毒， 包装即得。
实施例 42 土荆芥挥发油和水团花油自乳化软胶囊的制备
取明胶 100份加入 140份水中使其吸水膨胀， 另将 35份甘油加热至 70°C， 将膨胀的明胶加入， 搅摔， 熔融， 得明胶溶液， 保温待用；
称取实施例 8中的土荆芥挥发油和水团花油 735g， 菜籽色拉油 65g, 聚山梨 醇酯 60为 50g， 聚氧乙烯 （60) 氢化蓖麻油 120g， 70°C超声至均一、 透明的溶 液， 得原料油；
将明胶溶液与原料油装入压丸机，制成内含油状液体 lOOmg/粒的软胶囊， 软 胶囊定型、 干燥、 洗涤、 消毒， 包装即得。
实施例 43 土荆芥挥发油和水团花油自乳化硬胶囊的制备
称取实施例 1 中的土荆芥挥发油 800g， 实施例 6中的水团花油 150g， 菜籽 色拉油 40g， 聚氧乙烯 （35 ) 氢化蓖麻油 10g， 70°C超声至均一、 透明的溶液， 灌入硬胶囊壳， 制成 200mg/粒的胶囊。
实施例 44土荆芥挥发油和水团花油自乳化硬胶囊的制备
称取实施例 2中的土荆芥挥发油 450g， 实施例 6中的水团花油 150g， 菜籽 色拉油 100g， 聚氧乙烯 （35 ) 氢化蓖麻油 10g， 5(TC超声至均一、 透明的溶液， 灌入硬胶囊壳， 制成 270mg/粒的胶囊。
实施例 45 土荆芥挥发油和水团花油自乳化硬胶囊的制备
称取实施例 9中的土荆芥挥发油和水团花油 500g， 菜籽色拉油 80g， 聚氧乙 烯（60 )氢化蓖麻油 420g， 50°C超声至均一、 透明的溶液， 灌入硬胶囊壳， 制成 270mg/粒的胶囊。

Claims

权利要求：
1、 一种土荆芥提取物， 其特征在于， 通过 GC-MS分析， 所得质谱图谱中含有以 下两个峰：
峰 1 : 保留时间 8.0〜9.5分钟， 碎片离子质荷比为 121 , 93； 和
峰 2: 保留时间 9.0~10.0分钟， 碎片离子质荷比为 120， 119， 134。
2、 根据权利要求 1所述的土荆芥提取物， 其特征在于， 通过 GC-MS分析， 所得 质谱图谱中还含有以下两个峰：
峰 3: 保留时间 10.0~20.5分钟， 碎片离子质荷比为 119， 121， 136； 和 峰 4: 保留时间 15.0~20.5分钟， 碎片离子质荷比为 135， 43， 97。
3、 根据权利要求 2所述的土荆芥提取物， 其特征在于， 通过 GC-MS分析， 所得 质谱图谱中还含有以下两个峰：
峰 5: 保留时间 5.5~15.5分钟， 碎片离子质荷比为 93， 91； 和
峰 6: 保留时间 12.5~20.0分钟， 碎片离子质荷比为 71， 126， 69, 41。
4、根据权利要求 3所述的土荆芥提取物，其特征在于所述 GC-MS的分析条件是： 样品： 土荆芥提取物溶解在乙酸乙酯溶液中；
气相色谱条件：
色谱柱： 为 HP— 5MS 5%Phenyl Methyl Siloxane 60πιχ0.25ηιιηχ0.25μιη弹性石 英毛细管柱；
升温程序： 从 80°C开始， 经历 100°C， 150°C， 升温至 300°C升温程序结束； 汽化室温度： 250°C ; 载气： 高纯氦 （99.999%); 载气流速： l.OmL/分钟； 进样量： (乙酸乙酯溶液）； 分流比： 30:1 ;
质谱条件：
离子源： EI源； 离子源温度： 230°C ; 四极杆温度： 150°C ; 倍增器电压： 1781V; 接口温度： 280 °C ; 质量扫描范围： 10-550amuo
5、根据权利要求 1-4任一项所述的土荆芥提取物，其特征在于以重量百分比计含 有以下组分： α-萜品烯 15〜35%， 和对伞花烃 15~ 25%。
6、 根据权利要求 5 所述的土荆芥提取物， 其特征在于以重量百分比计， 其中还 含有以下组分： 驱蛔素 10~20%， 和 α-异松油烯 32〜40%。
7、 根据权利要求 6所述的土荆芥提取物， 其特征在于以重量百分比计含有以下 组分： α-萜品烯 20~30%， 对伞花烃 18-22%, 驱蛔素 12-18%, 和 α-异松油 烯 32~35%。
8、 根据权利要求 7所述的土荆芥提取物， 其特征在于以重量百分比计含有以下 组分： α-萜品烯 22~25%， 对伞花烃 19~ 21%， 驱蛔素 13〜15%, 和 α-异松油 烯 32-33% ο
9、 根据权利要求 6所述的土荆芥提取物， 其特征在于以重量百分比计还含有以 下组分： γ-萜品烯 0.5~0.7%和 /或拧檬烯 0.6〜0.8%。
10、 根据权利要求 9所述的土荆芥提取物， 其特征在于其中 γ-萜品烯和柠檬烯的 重量百分比分别为： γ-萜品烯 0.5~0.6%和柠檬烯 0.6~0.7%。
11、药物组合物， 该组合物含有权利要求 1-10任意一项所述的土荆芥提取物以及 药剂学可接受的辅料。
12、 根据权利要求 11所述的药物组合物， 其中还可以含有其它活性成分。
13、 根据权利要求 12的药物组合物， 其中所述的活性成分为水团花油。
14、 根据权利要求 11-13之任一项所述的药物组合物， 其中所述的药物组合物被 制成各种药用制剂形式。
15、 根据权利要求 14所述的药物组合物， 其中所述的制剂为胶丸， 该胶丸由胶 丸内容物和囊材组成，所述的胶丸内容物为权利要求 5-10任意一项所述的土荆芥 提取物和植物油。
16、 权利要求 15 所述的药物组合物， 其中所述的土荆芥提取物与植物油的重量 比为 1 :(1〜3)。
17、 根据权利要求 15所述的药物组合物， 其中所述的土荆芥提取物与植物油的 重量比为 1 :(1~2)。
18、 根据权利要求 15所述的药物组合物， 其中所述的土荆芥提取物与植物油的 重量比为 1 : 1。
19、 权利要求 15所述的药物组合物， 其中所述的胶丸囊材包括明胶和增塑剂， 其中增塑剂选自甘油、 木糖醇、 山梨醇和氢化玉米浆。
20、 权利要求 14所述的药物组合物， 其中所述的制剂形式为自乳化制剂， 该制 剂以重量百分比计含有下述组分： 土荆芥提取物或土荆芥提取物和水团花油 1-95%, 菜籽色拉油 4~39%， 表面活性剂 1~45%， 和助表面活性剂 0〜15%。
21、 根据权利要求 20所述的药物组合物， 其中各组分重量百分比为： 土荆芥提 取物或土荆芥提取物和水团花油 20~70%， 菜籽色拉油 10~30%， 表面活性剂 15-40%, 和助表面活性剂 5~10%。
22、 根据权利要求 20或 21所述的药物组合物， 其中所述的表面活性剂选自聚氧 乙烯蓖麻油缩合物、 聚氧乙烯氢化蓖麻油縮合物、 聚山梨醇酯、 磷脂； 所述的 助表面活性剂选自乙醇、 乙二醇、 丙二醇、 正丁醇、 异丙醇、 聚乙二醇 4000、 和 聚乙二醇 6000。
23、 根据权利要求 22所述的药物组合物， 其中所述的聚氧乙烯蓖麻油缩合物选 自： 聚氧乙烯 （35 ) 蓖麻油和聚氧乙烯 （60) 蓖麻油； 所述的聚氧乙烯氢化蓖麻 油缩合物选自聚氧乙烯 （35 ) 氢化蓖麻油和聚氧乙烯 （60) 氢化蓖麻油； 所述的 聚山梨醇酯选自聚山梨醇酯 60和聚山梨醇酯 80; 所述的磷脂选自蛋黄卵磷脂、 大豆卵磷脂、 二棕榈酰磷脂酰胆碱、 二硬脂酰磷脂酰胆碱和二肉豆蔻酰磷脂酰胆 碱。
24、 根据权利要求 11所述药物组合物的制备方法， 该方法包括以下步骤：
a. 土荆芥经过常规提取方法得土荆芥提取物；
b. 加入药剂学上接受的辅料以常规制备方法制成所需制剂。
25、 根据权利要求 24所述的制备方法， 其中所述土荆芥提取物的制备方法包括 将土荆芥种子或全草放入蒸馏锅内，在收集器内通蒸气，保持提取温度 85~100°C， 蒸馏 40分钟， 收集土荆芥挥发油。
26、 根据权利要求 25所述的药物组合物的制备方法， 其中所制备的组合物是胶 丸， 该制备方法包括取药用明胶和增塑剂， 于蒸馏水中溶解过滤， 制成明胶溶液; 用植物油溶解稀释土荆芥挥发油， 得原料油； 将原料油与明胶溶液加入胶丸生产 设备中制成内含油状液体的胶丸。
27、 根据权利要求 26所述的制备方法， 其特征在于， 其中所述的增塑剂选自甘 油、 木糖醇、 山梨醇和氢化玉米浆。
28、 根据权利要求 24-25任意一项所述的药物组合物的制备方法， 其中所制备的 组合物是自乳化制剂， 该制备方法包括按处方量称取土荆芥提取物或土荆芥提取 物和水团花油、 菜籽色拉油、 表面活性剂或者再加上助表面活性剂， 30〜80°C水 浴加热或者超声至均一、 透明的溶液， 再制备成软胶囊或者硬胶囊制剂。
29、 根据权利要求 28所述的制备方法， 其中所述表面活性剂选自聚氧乙烯蓖麻 油缩合物、 聚氧乙烯氢化蓖麻油缩合物、 聚山梨醇酯、 磷脂。
30、 根据权利要求 29所述的制备方法， 其特征在于， 所述聚氧乙烯蓖麻油缩合 物选自聚氧乙烯 （35 )蓖麻油、 聚氧乙烯 （60) 蓖麻油； 所述聚氧乙烯氢化蓖麻 油縮合物选自聚氧乙烯 （35 ) 氢化蓖麻油、 聚氧乙烯 （60) 氢化蓖麻油； 所述聚 山梨醇酯选自聚山梨醇酯 60、 聚山梨醇酯 80; 所述磷脂选自蛋黄卵磷脂、 大豆 卵磷脂、 二棕榈酰磷脂酰胆碱、 二硬脂酰磷脂酰胆碱、 二肉豆蔻酰磷脂酰胆碱。
31、 根据权利要求 28所述的制备方法， 其特征在于， 所述的助表面活性剂选自 乙醇、 乙二醇、 丙二醇、 正丁醇、 异丙醇、 聚乙二醇 4000、 聚乙二醇 6000。
32、权利要求 1-10任意一项所述的土荆芥提取物或权利要求 11-23任意一项所述 的含有土荆芥提取物的药物组合物在制备治疗幽门螺旋菌感染引起的胃炎、 胃溃 疡药物中的应用。
PCT/CN2006/003691 2005-12-31 2006-12-29 Composition pharmaceutique contenant un extrait de chenopodium ambrosioides et son procédé de préparation et son application WO2007076699A1 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
KR1020087018649A KR101164516B1 (ko) 2005-12-31 2006-12-29 양명아주 추출물을 함유하는 약학 조성물, 및 이의 제조방법 및 용도
JP2008547835A JP5844954B2 (ja) 2005-12-31 2006-12-29 アリタソウの抽出物を含有する医薬組成物、それらの製造方法
US12/159,609 US8361515B2 (en) 2005-12-31 2006-12-29 Extracts of Chenopodium ambrosioides L., the compositions comprising said extracts, the preparing process and application thereof
EP06840721A EP1982705B8 (en) 2005-12-31 2006-12-29 Pharmaceutical composition containing chenopodium ambrosioides extract and its preparation process and application
CA2635610A CA2635610C (en) 2006-12-29 2006-12-29 Extracts of chenopodium ambrosioides l., the compositions comprising said extracts, the preparing process and application thereof
HK08111964.1A HK1119938A1 (en) 2005-12-31 2008-10-30 Pharmaceutical composition containing chenopodium ambrosioides extract and its preparation process and application
US13/725,265 US8586108B2 (en) 2005-12-31 2012-12-21 Extracts of Chenopodium ambrosioides L., the compositions comprising said extracts, the preparing process and application thereof

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
CN2005101353590A CN1990007B (zh) 2005-12-31 2005-12-31 一种治疗胃病的组合物、制备方法及其用途
CN2005101353586A CN1990006B (zh) 2005-12-31 2005-12-31 一种土荆芥提取物、其制剂、制备方法与用途
CN200510135359.0 2005-12-31
CN200510135358.6 2005-12-31
CN200610136500.3 2006-10-30
CN2006101365003A CN101172132B (zh) 2006-10-30 2006-10-30 一种治疗胃病的自乳化制剂及其制备方法

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/159,609 A-371-Of-International US8361515B2 (en) 2005-12-31 2006-12-29 Extracts of Chenopodium ambrosioides L., the compositions comprising said extracts, the preparing process and application thereof
US13/725,265 Division US8586108B2 (en) 2005-12-31 2012-12-21 Extracts of Chenopodium ambrosioides L., the compositions comprising said extracts, the preparing process and application thereof

Publications (1)

Publication Number Publication Date
WO2007076699A1 true WO2007076699A1 (fr) 2007-07-12

Family

ID=38227910

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2006/003691 WO2007076699A1 (fr) 2005-12-31 2006-12-29 Composition pharmaceutique contenant un extrait de chenopodium ambrosioides et son procédé de préparation et son application

Country Status (7)

Country Link
US (2) US8361515B2 (zh)
EP (1) EP1982705B8 (zh)
JP (1) JP5844954B2 (zh)
KR (1) KR101164516B1 (zh)
HK (1) HK1119938A1 (zh)
MY (1) MY148473A (zh)
WO (1) WO2007076699A1 (zh)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1982705B8 (en) 2005-12-31 2012-08-22 Tasly Pharmaceutical Group Co., Ltd. Pharmaceutical composition containing chenopodium ambrosioides extract and its preparation process and application
EP2440061B1 (en) 2009-06-12 2018-12-05 Bayer Cropscience LP Methods of inhibiting, preventing, killing and/or repelling insects using simulated blends of chenopodium extracts
JP2012077033A (ja) * 2010-10-01 2012-04-19 Kinki Univ ヘリコバクターピロリの運動能阻害剤
EP2714021A1 (en) 2011-02-02 2014-04-09 Max Reynolds Composition of monoterpenoids having bactericidal properties
US9107420B2 (en) 2014-01-13 2015-08-18 Eliana Ellern Animal shampoo
CN104474350A (zh) * 2014-12-20 2015-04-01 济南伟传信息技术有限公司 一种治疗胃溃疡的茶
EP3423033A4 (en) * 2016-03-04 2020-01-01 Sharon Anavi-Goffer SELF-EMULSIFYING COMPOSITIONS OF CB2 RECEPTOR MODULATORS
JP2021035912A (ja) * 2017-12-20 2021-03-04 石原産業株式会社 有害生物防除用組成物及び有害生物の防除方法
CN110133140B (zh) * 2019-05-23 2022-07-12 吉林化工学院 一种白鲜地上部分挥发油成分鉴定及其抑菌活性研究

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1131556A (zh) * 1995-03-23 1996-09-25 张涌川 一种胃康胶丸及其制备方法
CN1506118A (zh) * 2002-12-06 2004-06-23 苏少宁 一种用于消化道检查窥视设备的消毒液

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5039699A (en) * 1989-03-27 1991-08-13 Lederle (Japan), Ltd. Anti-peptic ulcer agent
US5696169A (en) * 1992-03-13 1997-12-09 Otsuka Pharmaceutical Co., Ltd. Antibacterial and antifungal activity method, therapeutic method of infectious diseases and preserving method of cosmetics
AU1881600A (en) * 1998-12-23 2000-07-31 Alza Corporation Dosage forms comprising porous particles
US20030091657A1 (en) * 2000-03-17 2003-05-15 Helene Chiasson Plant acaricidal compositions and method using same
CZ20033341A3 (cs) * 2001-06-21 2004-10-13 Pfizeráproductsáinc Samoemulgující se kompozice inhibitorů přenosového proteinu cholesterylesteru
JP4081312B2 (ja) * 2002-06-28 2008-04-23 佐藤製薬株式会社 外用抗真菌剤
CN101172132B (zh) 2006-10-30 2011-10-05 天津天士力制药股份有限公司 一种治疗胃病的自乳化制剂及其制备方法
RU2423111C2 (ru) 2005-12-31 2011-07-10 Тяньцзинь Тасли Фармасьютикл Ко., Лтд. ЭКСТРАКТЫ ПРИМЕНЯЕМОГО В КИТАЙСКОЙ МЕДИЦИНЕ РАСТЕНИЯ Chenopodium ambrosioides L., КОМПОЗИЦИИ, ВКЛЮЧАЮЩИЕ УПОМЯНУТЫЕ ЭКСТРАКТЫ, СПОСОБ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЕ
CN1990006B (zh) 2005-12-31 2011-10-05 天津天士力制药股份有限公司 一种土荆芥提取物、其制剂、制备方法与用途
EP1982705B8 (en) 2005-12-31 2012-08-22 Tasly Pharmaceutical Group Co., Ltd. Pharmaceutical composition containing chenopodium ambrosioides extract and its preparation process and application

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1131556A (zh) * 1995-03-23 1996-09-25 张涌川 一种胃康胶丸及其制备方法
CN1506118A (zh) * 2002-12-06 2004-06-23 苏少宁 一种用于消化道检查窥视设备的消毒液

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
CHEN; ZHENMIN, LIAONING JOURNAL OF TRADITIONAL CHINESE MEDICINE, vol. 22, no. 10, 1995, pages 472
HUANG ET AL., NORTHWEST PHARMACEUTICAL JOURNAL, vol. 13, no. 1, 1998, pages 33 - 34
HUANG X.F. ET AL.: "Study on Chemical Constituents of Volatile Oil from Chenopodium ambrosioides L", JOURNAL OF CHINA PHARMACEUTICAL UNIVERSITY, vol. 33, no. 3, 2002, pages 256 - 257 *
LIU, JUNYING; MA, CAILIAN, JOURNAL OF PRACTICAL MEDICAL TECHNIQUES, vol. 5, no. 7, 1998, pages 542 - 544
MO; JIANZHONG, CHINESE JOURNAL OF DIGESTION, vol. 15, no. 3, 1995, pages 164
RECENT DEVELOPMENTS IN SCIENCE & TECHNOLOGY ABROAD, vol. 4, 2003, pages 44 - 45
WANG R.M. ET AL.: "Studies on Anti-gastric Ulcer Action of Zhonghuaweikang in Rats Mice and Inhibitory Effect on Helicobacter Pylori", STRAIT PHARMACEUTICAL JOURNAL, vol. 11, no. 2, 1999, pages 16 - 18 *
WARREN JR; MARSHALL BJ., LANCET, vol. 1, 1983, pages 1273 - 1275
XIONG X.F. ET AL.: "STUDIES ON THE CHEMICAL CONSTITUENTS OF THE VOLATILE OIL FROM CHENOPODIUM AMBROSIOIDES L. GROWN IN HUBEI", JOURNAL OF WUHAN BOTANICAL RESEARCH, vol. 17, no. 3, 1999, pages 244 - 248 *
XU; LING, JOURNAL OF FIRST MILITARY MEDICAL UNIVERSITY, vol. 15, no. 4, 1995, pages 360 - 361

Also Published As

Publication number Publication date
US8586108B2 (en) 2013-11-19
MY148473A (en) 2013-04-30
KR20090019760A (ko) 2009-02-25
EP1982705A1 (en) 2008-10-22
EP1982705B1 (en) 2012-07-18
US20130178516A1 (en) 2013-07-11
US8361515B2 (en) 2013-01-29
US20090130203A1 (en) 2009-05-21
JP5844954B2 (ja) 2016-01-20
JP2009522208A (ja) 2009-06-11
EP1982705B8 (en) 2012-08-22
HK1119938A1 (en) 2009-03-20
KR101164516B1 (ko) 2012-07-13
EP1982705A4 (en) 2009-07-29
EP1982705A8 (en) 2008-12-10

Similar Documents

Publication Publication Date Title
WO2007076699A1 (fr) Composition pharmaceutique contenant un extrait de chenopodium ambrosioides et son procédé de préparation et son application
CN1196477C (zh) 用于口服给药的药物组合物
CN1990006B (zh) 一种土荆芥提取物、其制剂、制备方法与用途
CN101890114A (zh) 一种有抑菌、抗炎和止血作用的黎药提取物及组合物和其制备方法
CN106822166B (zh) 一种防治糖尿病和高脂血症的药物及其在制药中的应用
US10548940B2 (en) Pharmaceutical composition for controlling blood lipids and body weight, and use thereof
CN105796764B (zh) 黄荆子总木脂素制备方法及其用途
RU2423111C2 (ru) ЭКСТРАКТЫ ПРИМЕНЯЕМОГО В КИТАЙСКОЙ МЕДИЦИНЕ РАСТЕНИЯ Chenopodium ambrosioides L., КОМПОЗИЦИИ, ВКЛЮЧАЮЩИЕ УПОМЯНУТЫЕ ЭКСТРАКТЫ, СПОСОБ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЕ
CN113214207B (zh) 橙皮素与甜菜碱共晶物a及制备方法和其组合物与用途
CN104435293B (zh) 异型南五味子总三萜乙醇提取物在制备抗关节炎药物中的应用
CN1278731C (zh) 复方柴胡药物制剂
CN112603982A (zh) 一种抑制前列腺增生的组合物
CA2635610C (en) Extracts of chenopodium ambrosioides l., the compositions comprising said extracts, the preparing process and application thereof
CN100363018C (zh) 金银花软胶囊制剂及其制备方法
CN1990007B (zh) 一种治疗胃病的组合物、制备方法及其用途
WO2009074065A1 (fr) Utilisation de daphné primeverosyl genkwanine et de plantes de daphné
CN111265618A (zh) 鼓槌石斛提取物及毛兰素的医药用途
CN104557818B (zh) 一种穿心莲内酯化合物及含有该化合物的滴丸和软胶囊
CN113509465A (zh) 一种具有抗高血压作用的组合物及其应用
CN104491849B (zh) 大蒜辣素多层肠溶片作为制备治疗心肌梗死疾病药物的应用
CN103989753A (zh) 一种治疗良性前列腺增生的药物组合物
CN114469934A (zh) 一种组合物及其药物制剂
CN116650421A (zh) 一种迷迭香固体分散剂及其制备方法和应用
CN1853675A (zh) 复方水飞蓟素滴丸及其制备方法
CN100382783C (zh) 补骨脂滴丸及其制备方法

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2635610

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2008547835

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008130841

Country of ref document: RU

WWE Wipo information: entry into national phase

Ref document number: 2006840721

Country of ref document: EP

Ref document number: 1020087018649

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 12159609

Country of ref document: US